

CURRICULUM VITAE

Jacquelyn Louise Bainbridge

I. GENERAL INFORMATION

Home address: 5101 East Princeton Avenue
Englewood, Colorado 80113

Business address: University of Colorado Denver
School of Pharmacy, Department of Clinical Pharmacy
Campus Box C238, and
Department of Neurology,
SOP C238-L15
Academic Office 1 12631 E.17th Ave
Room # L15-1419
Aurora, Colorado 80045

Telephone: Home (303) 758-8033
Office School of Pharmacy (303) 724-2617
FAX (303) 724-2627

II. EDUCATION

September 1, 1995 - August 31, 1996 Specialty Residency in Neurology
University of Colorado
College of Pharmacy
Denver, Colorado

July 1, 1993 - June 30, 1995 Doctor of Pharmacy
University of Colorado
School of Pharmacy
Denver, Colorado

1986 - 1988 Bachelor of Science in Pharmacy
Ohio Northern University
School of Pharmacy
Ada, Ohio

1988 Correspondence, Liberal Arts
Pennsylvania State University
University Park, Pennsylvania

1981 - 1986

Combined Sciences, and
Medical Technology
Youngstown State University
Youngstown, Ohio

III. PROFESSIONAL CREDENTIALS

A. Licensure

Colorado, March 15th, 1989 License # 12682

B. Certifications

Advanced Cardiac Life Support (ACLS), 1982 - present
Instructor Basic Electrocardiogram Monitoring for Assessment and
Management Certification, 1991 - present
Instructor, Basic Life Support, 1991 – present

IV. PROFESSIONAL EXPERIENCE

<u>YEAR</u>	<u>TITLE</u>	<u>INSTITUTION</u>
1980 - 1986	Medical Intensive Care Ward Clerk	Saint Elizabeth's Medical Center
1988 - 1989	Pharmacy Graduate Intern	University of Colorado Health Sciences Center
1989 - 1991	Intensive Care Unit Pharmacist	University of Colorado Health Sciences Center
1991 - 1996	Clinical Pharmacist - Critical Care	University of Colorado Health Sciences Center
1992 - 1993	Nutritional Support Service Pharmacist	University of Colorado Health Sciences Center

V. ACADEMIC APPOINTMENTS

<u>YEAR</u>	<u>TITLE</u>	<u>INSTITUTION</u>
1995	Visiting Assistant Professor	University of California, San Francisco
1996 – 2003	Assistant Professor	University of Colorado School of Pharmacy and Department of Neurology
2003 – 2008	Associate Professor	University of Colorado School of Pharmacy and Department of Neurology

2009 –present Professor

University of Colorado Skaggs
School of Pharmacy and
Pharmaceutical Sciences Department
of Clinical Pharmacy and
Department of Neurology

VI. TEACHING ACTIVITY

A. Undergraduate Courses

Fall 1995

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

University of Colorado School of Nursing; Neurodiagnostics
Cardiopulmonary Resuscitation (CPR)

Spring 1996

University of Colorado School of Pharmacy
PHPR 4610 Pharmacotherapeutics II (5 credit hours)

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

Spring 1997

University of Colorado School of Pharmacy
PHPR 4610 Pharmacotherapeutics II (5 credit hours)

University of Colorado School of Pharmacy
PHPR 4530 Pharmacology (4 credit hours)

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

Spring 1998

University of Colorado School of Pharmacy
PHPR 4610 Pharmacotherapeutics II (5 credit hours)

University of Colorado School of Pharmacy
PHPR 4530 Pharmacology (4 credit hours)

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

Spring 1999

University of Colorado School of Pharmacy
PHPR 4610 Pharmacotherapeutics II (5 credit hours)

University of Colorado School of Pharmacy
PHPR 4530 Pharmacology (4 credit hours)

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

Spring 2000

University of Colorado School of Pharmacy
PHPR 4610 Pharmacotherapeutics II (5 credit hours)

University of Colorado School of Pharmacy
PHPR 4530 Pharmacology (4 credit hours)

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

Spring 2001

University of Colorado School of Pharmacy
PHRD 4770 IOS VIII (4 credit hours)

University of Colorado School of Pharmacy
PHPR 4610 Pharmacotherapeutics II (5 credit hours)

University of Colorado School of Pharmacy
PHPR 4530 Pharmacology (4 credit hours)

Professional and Graduate Courses

Spring 1996

Cardiopulmonary Resuscitation (CPR), Pharm.D.

PRDO 5620 Pharm.D., Nursing, Neurodiagnostics

University of Colorado School of Medicine
Department of Neurology lecture series

Spring 1997

University of Colorado School of Pharmacy
PHPR 5420 Advanced Pharmacotherapeutics (6 credit hours)

University of Colorado School of Pharmacy
PRDO 5250 Skill Laboratory (3 hours per session)

University of Colorado School of Pharmacy
PHPR 5220 Special Topics and Case Studies in
Pharmacotherapeutics I

University of Colorado School of Nursing - Masters/Doctorate,
N6223 Neurology related Pharmacology (7.5 hours)

Cardiopulmonary Resuscitation (CPR), Pharm.D.
PRDO 5620 Pharm.D., Nursing, and Neurodiagnostics (6 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series

Spring 1998

University of Colorado School of Pharmacy, Non-Traditional Pharm.D.
PRDO 5350 Pathophysiology and Therapeutics Neurology

University of Colorado School of Pharmacy
PHPR 5420 Advanced Pharmacotherapeutics (6 credit hours)

University of Colorado School of Pharmacy
PRDO 5250 Skill Laboratory (3 hours per session)

Cardiopulmonary Resuscitation (CPR), Pharm.D.
PRDO 5620 Pharm.D., Nursing, and Neurodiagnostics (6 credit hours)

University of Colorado School of Nursing - Masters/Doctorate,
N6223 Neurology related Pharmacology (7.5 hours)

University of Colorado School of Medicine

Department of Neurology lecture series

Spring 1999

University of Colorado School of Pharmacy
PHPR 5420 Advanced Pharmacotherapeutics (6 credit hours)

University of Colorado School of Pharmacy
PRDO 5250 Skill Laboratory (3 hours per session)

University of Colorado School of Medicine
Department of Neurology lecture series

Spring 2000

University of Colorado School of Pharmacy
PHPR 5420 Advanced Pharmacotherapeutics (6 credit hours)

University of Colorado School of Pharmacy
PRDO 5250 Skill Laboratory (3 hours per session)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

University of Colorado School of Medicine
Department of Neurology lecture series

Fall 2000

University of Colorado School of Pharmacy, Non-traditional Pharm.D.
PRDO 5350 Pathophysiology and Therapeutics Neurology

Spring 2001

University of Colorado School of Pharmacy
PHPR 5420 Advanced Pharmacotherapeutics (6 credit hours)

University of Colorado School of Pharmacy
PRDO 5450 Skill Laboratory (3 hours per session)

University of Colorado School of Pharmacy

PRDO 5600 Pathophysiology

University of Colorado School of Pharmacy
PHRD 4770 IOS VIII (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

University of Colorado School of Medicine
Department of Neurology lecture series

Spring 2002

University of Colorado School of Pharmacy
PRDO 5450 Skill Laboratory (3 hours per session)

University of Colorado School of Pharmacy
PHRD 5660 Comprehensive Patient Care (5 credit hours)

University of Colorado School of Pharmacy
PHRD 4770 IOS VIII (4 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

Spring 2003

University of Colorado School of Pharmacy
PRDO 5450 Skill Laboratory (3 hours per session)

University of Colorado School of Pharmacy
PHRD 5660 Comprehensive Patient Care (5 credit hours)

University of Colorado School of Pharmacy
PHRD 4770 IOS VIII (4 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

Fall 2004

University of Colorado School of Pharmacy
PHRD 4450 Advanced Drug Literature Evaluation

University of Colorado School of Pharmacy
PRDO 5450 Skill Laboratory (3 hours per session)

University of Colorado School of Pharmacy
PHRD 5660 Comprehensive Patient Care (5 credit hours)

University of Colorado School of Pharmacy
PHRD 4770 IOS VIII (4 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

Spring 2005

University of Colorado School of Pharmacy
PHRD 4770 Coordinated and teaching IOS VIII (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series

University of Colorado School of Medicine
Department of Neurosurgery lecture series

Fall 2005

University of Colorado School of Pharmacy
PHRD 5710 Coordinated IOS X (4 credit hours)

University of Colorado School of Pharmacy
PHRD 5200 Coordinated Seminar (1 credit hour)

University of Colorado School of Physical Therapy
PHPR 6586 Pharmacology (4 credit hours)

University of Colorado School of Pharmacy
PRDO 5450 Skill Laboratory (3 hours per session)

Spring 2006

University of Colorado School of Pharmacy
PHRD 5200 Coordinated Seminar (1 credit hour)

University of Colorado School of Pharmacy
PHRD 4770 Coordinated and teaching IOS VIII (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series

University of Colorado School of Pharmacy
PHRD 5660 Comprehensive Patient Care (5 credit hours)

Fall 2006

University of Colorado School of Pharmacy
PHRD 5200 Coordinated Seminar (1 credit hour)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

Spring 2007

University of Colorado School of Pharmacy
PHRD 5200 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

University of Colorado School of Pharmacy
PHRD 4770 Coordinated and teaching IOS VIII/ 13 lecture hours (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 12 lecture hours

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Medicine
Department of Neurosurgery lecture series (2 lecture hours)

University of Colorado School of Pharmacy
PHRD 5660 Comprehensive Patient Care/ 10 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 5450 Skills Laboratory (3 credit hours)

Fall 2007

University of Colorado School of Pharmacy
PHRD 5200 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

Spring 2008

University of Colorado School of Pharmacy
PHRD 4770 Coordinated and teaching IOS VIII/ 13 lecture hours (4 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 5350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Medicine
Department of Neurosurgery lecture series (2 lecture hours)

University of Colorado School of Pharmacy
PHRD 5660 Comprehensive Patient Care/ 10 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 5450 Skills Laboratory (3 credit hours)

Fall 2008

University of Colorado School of Pharmacy
PHRD 5200/5250 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 12 lecture hours

Spring 2009

University of Colorado School of Pharmacy
PHRD 6770 Coordinated and teaching IOS VIII/ 13 lecture hours (4 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Medicine
Department of Neurosurgery lecture series (2 lecture hours)

University of Colorado School of Pharmacy
PHRD 7660 Comprehensive Patient Care/ 4 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 7450 Skills Laboratory (3 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 4 lecture hours

Fall 2009

University of Colorado Denver
Ethics Multidisciplinary Facilitation PRMD 6000

University of Colorado Denver
Behavioral, Geriatric, and Special Dentistry DSAD 7720

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 6 lecture hours

University of Colorado School of Pharmacy
PHRD 7200/7250 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

Spring 2010

University of Colorado School of Pharmacy
PHRD 6770 Coordinated and teaching IOS VIII/ 13 lecture hours (4 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Medicine
Department of Neurosurgery lecture series (2 lecture hours)

University of Colorado School of Pharmacy
PHRD 7660 Comprehensive Patient Care/ 4 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 7450 Skills Laboratory (3 credit hours)

University of Colorado School of Nursing

Cardiopulmonary Resuscitation (CPR) 4 lecture hours

Fall 2010

University of Colorado Denver
Ethics Multidisciplinary Facilitation PRMD 6000

University of Colorado Denver
Behavioral, Geriatric, and Special Dentistry DSAD 7720

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 6 lecture hours

University of Colorado School of Pharmacy
PHRD 7200/7250 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

Spring 2011

University of Colorado School of Pharmacy
PHRD 6770/6770 Coordinated and teaching IOS VII/VIII/ 13 lecture hours (6 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Pharmacy
PHRD 7660 Comprehensive Patient Care/ 4 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 7450 Skills Laboratory (3 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 4 lecture hours

Fall 2011

University of Colorado Denver

Ethics Multidisciplinary Facilitation PRMD 6000

University of Colorado Denver
Behavioral, Geriatric, and Special Dentistry DSAD 7720

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 6 lecture hours

University of Colorado School of Pharmacy
PHRD 7200/7250 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

Spring 2012

University of Colorado School of Pharmacy
PHRD 6770/6770 Coordinated and teaching IOS VII/VIII/ 13 lecture hours (6 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Pharmacy
PHRD 7660 Comprehensive Patient Care/ 4 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 7450 Skills Laboratory (3 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 4 lecture hours

Fall 2012

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 6 lecture hours

University of Colorado School of Pharmacy
PHRD 7200/7250 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

Spring 2013

University of Colorado School of Pharmacy
PHRD 6770/6770 Coordinated and teaching IOS VII/VIII/ 13 lecture hours (6 credit hours)

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

Women's Health Elective (2 credit hours)

University of Colorado School of Medicine
Department of Neurology lecture series (4 lecture hours)

University of Colorado School of Pharmacy
PHRD 7660 Comprehensive Patient Care/ 4 lecture hours (5 credit hours)

University of Colorado School of Pharmacy
PRDO 7450 Skills Laboratory (3 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 4 lecture hours

Physical Therapy
Multiple Sclerosis Drug Therapy and Parkinson's Disease Drug Therapy
(2 lecture hours)

Fall 2013

University of Colorado School of Pharmacy
Advanced Disease State Management 5
PRDO 7350 Nontraditional Pharm.D. Program (4 credit hours)

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 6 lecture hours

University of Colorado School of Pharmacy
PHRD 7200/7250 Coordinated Seminar/ 1 to 2 hours per week (1 credit hour)

hour)

University of Colorado School of Pharmacy
Pharmacogenomics PHRD 7025 (1 hour lecture)

Spring 2014

University of Colorado School of Pharmacy
PHRD 6995 Pharmacotherapy 5
13 lecture hours (4 credit hours)
Coordinator

University of Colorado School of Pharmacy
PHRD 7880 Women's Health
2 hours (2 credit hour course)

Fall 2014

University of Colorado School of Nursing
Cardiopulmonary Resuscitation (CPR) 6 lecture hours

University of Colorado School of Pharmacy
PHRD 7820 Managing Your Pharmacy Career
2 hour lecture (2 credit hour course)

University of Colorado School of Pharmacy
PHRD 7025 Pharmacogenomics
2 hours (2 credit hour course)

Spring 2015

University of Colorado School of Pharmacy
PHRD 7880 Women's Health
2 hours (2 credit hour course)

University of Colorado School of Pharmacy
PHRD 6995 Pharmacotherapy 5
13 lecture hours (4 credit hours)
Coordinator

B. Student Preceptor

Undergraduate

1991 - 1996 University of Colorado Health Sciences Center

Critical Care and Hospital Pharmacy

Spring 1998

Rotation 1	Lori Scates	01/05/98-02/13/98
Rotation 2	Henri Acosta	02/16/98–03/27/98
Rotation 3	Soussan Yazdi	03/30/98–05/08/98

Spring 1999

Rotation 1	Orlando Garcia	01/11/99–02/19/99
Rotation 3	Guerra, Thomas	04/05/99–05/14/99

Spring 2000

Rotation 1	Jessica Sterna	01/10/00–03/03/00
------------	----------------	-------------------

Graduate

Summer 1997

Rotation 1	Scott Pollock	06/02/97–07/11/97
Rotation 2	Kelli Edwards-Malone	07/14/97–08/22/97

Summer/Fall 1997

Rotation 4	Alice Park	10/06/97–11/14/97
	Julie Himstreet	10/01/07–12/31/97

Spring 1997

Rotation 5	Nicole Mrosz	11/17/97–01/09/98
Rotation 6	Linda Keyser	01/12/98–02/20/98
	Helen Brantley	02/01/98–02/28/98
Rotation 7	Stacy LaClaire	02/23/98–04/03/98
	Laura Borgelt	03/01/98–06/30/98
Rotation 8	Lisa Kranak	04/06/98–05/15/98

Summer/ Fall 1998

Neurology Specialty Resident

1 year	Scott Pollock	09/98-10/99
Rotation 1	Dennis Teng John Rafi (MCV)	07/13/98–08/21/98 07/13/98–08/21/98
Rotation 2	Pamela Knutson	07/13/98–08/14/98
Rotation 4	James Adams	11/16/98–01/08/99

Spring 1998

Rotation 5	Trang Bui	01/11/99–02/19/99
Rotation 7	Jill Chappell	04/05/99–05/14/99

Summer/Fall 1999

Neurology Clinical Research Fellow

1 year	Scott Pollock	09/99-10/00
--------	---------------	-------------

Neurology Specialty Resident

1 year	Sunita Dergalust	09/99-10/00
--------	------------------	-------------

Summer/Fall 1999

Rotation 2	Sunita Dergalust University of Washington	09/01/99–10/01/99
Rotation 3	Thang Than	10/10/99–10/14/99
Rotation 4	Loi Chau Edina Hall	11/16/98–02/19/99 11/16/98–01/08/99

Spring 2000

Rotation 5	Loi Chau	01/10/00–02/18/00 (Clinical Research)
	Miles Doane	01/10/00–02/18/00
	Cindy James	01/10/00–02/18/00

Rotation 6	Elham Tabarsi University of Washington	02/15/00–03/10/00
	Amber Gilbert University of Montana	03/06/00–03/31/00

Summer/Fall 2000

Neurology Specialty Resident

1 year	Janina Janes	06/00-07/01
--------	--------------	-------------

Rotation 1	Jennifer McCullough	11/1/00-11/30/00
------------	---------------------	------------------

General Practice Resident

Summer/Fall 2000

Rotation 3	Kathleen Anderson	10/02/00-11/10/00
------------	-------------------	-------------------

Rotation 4	Claire Avante Samantha Ries	11/13/00-01/05/01 11/13/00-01/05/01
------------	--------------------------------	--

Fall 2000

Portfolio (PHRD 5300)	Judith Kim	
---------------------------------	------------	--

Spring 2001

Rotation 5	Shelby Wilson Eric Smith	01/08/01-02/16/01 01/08/01-02/16/01
------------	-----------------------------	--

Non-traditional	Clark Lyda	01/23/01
------------------------	------------	----------

Portfolio	Judith Kim	
------------------	------------	--

Fall 2001

Practice resident	Carolyn Wong	07/01–12/21/01
--------------------------	--------------	----------------

Rotation 4	Joseph Brougham Jinhee Ahn	11/12/01-01/04/02 11/12/01-01/04/02
------------	-------------------------------	--

Portfolio Judith Kim (P2/P3)

Spring 2002

Practice resident	Dan Bestul	01/04/02-06/30/02
Rotation 5	Michele Fittje	01/07/02-02/15/02
Rotation 6	Jennifer Bailey Cari Bennet	02/18/02-03/29/02 02/18/02-03/29/02

Fall 2002

Rotation 2	Monika Majer Jenny Nguyen	07/08/02-08/16/02 07/08/02-08/16/02
Rotation 5	Michelle Libner Jenifer McGovern	11/11/02-12/20/02 11/11/02-12/20/02

Spring 2003

Psychiatry Resident	Suzie Cala	01/06/03-02/14/03
Rotation 6	Hal Piwonka Rachelle Roa	01/06/03-02/14/03 01/06/03-02/14/03
Rotation 7	Christine Saar Kerry Hannon	02/17/03-03/31/03 02/17/03-03/31/03

Neurology residents

Josh Renkin, M.D.	03/03/03-03/31/03
Michael Ament, M.D.	03/03/03-03/31/03

Summer 2003

Rotation 1	Rachel Konz Tameko Wilder	05/26/03-07/04/03 05/26/03-07/04/03
Rotation 3	Melinda Aragon	08/18/03-09/26/03

Fall 2003

VA Practice resident	James Gasper	10/01/03-10/31/03
UOC Practice resident	Stephen Craul	06/01/03-12/30/03
Psychiatry Resident	Rachel Miles	11/10/03-01/02/04
Rotation 5	Margaret Henderson Jared Gallegos	11/10/03-12/19/03 11/10/03-12/19/03

Spring 2004

Rotation 6	Jennifer Fortunato Christa Dierking	01/12/04-02/20/04 01/12/04-02/20/04
Rotation 7	Jennifer Stone	02/23/04-03/28/04

Summer 2004

Rotation 1	Stefanie Muraoka Toan Tran Erik Makineni	05/31/04-07/09/04 05/31/04-07/09/04 05/31/04-07/09/04
------------	--	---

Fall 2004

Rotation 3	Truc Le Heather Zinser	08/23/04-10/01/04 08/23/04-10/01/04
VA Resident	Jennifer Schuh	09/01/04-10/01/04
Rotation 4	Jennifer Trackwell Chris Habermann	10/04/04-11/12/04 10/04/04-11/12/04
Rotation 5	Daniel Moreno Maria Shulga	11/15/04-12/24/04 11/15/04-12/24/04

Spring 2005

Rotation 6	Nerissa Moore Christopher Fernandez	01/10/05-02/18/05 01/10/05-02/18/05
------------	--	--

Rotation 7 Angie Suliman 02/21/05-04/01/05

VA Resident Valerie Kuva 03/01/05-04/01/05

Summer 2005

Rotation 2 Davy To 07/11/05-08/19/05
Gregory Palmrose 07/11/05-08/19/05

Fall 2005

Rotation 3 Paul O'Donnell 08/22/05-09/30/05
Valentina Chesnokova 08/22/05-09/30/05
Kathleen McCartney 08/29/05-10/22/05

Rotation 4 Meghann Edwards 10/03/05-11/11/05
Henna Patel 10/03/05-11/11/05

Rotation 5 Le-Ta, Jenny-Anh 11/14/05-12/23/05
Dawn Lefevre 11/14/05-12/23/05
Bryan Killam 12/01/05-02/01/06

Spring 2006

Rotation 6 Hoang Phuong Nguyen 01/09/06-02/17/06
Jason Strasser 01/09/06-02/17/06

UOC Practice resident Joe Vande Griend 01/03/06-01/31/06
UOC Practice resident Devon Flynn 02/03/06-02/28/06

Rotation 7 Roy Brunson 02/20/06-03/31/06
Francis Macalalag 02/20/06-03/31/06

UOC Practice resident Gretchen Imel 03/01/06-03/31/06

Fall 2006

Non-traditional Anita Berk 08/21/06-09/29/06
Rotation 3 Sarah Johnson 08/21/06-09/29/06
Leann Nguyen 08/21/06-09/29/06

Rotation 4 Katherine Hays 10/02/06-11/10/06
Keith Kapp 10/02/06-11/10/06

Rotation 5 Jing An 11/13/06-12/22/06
Jeffrey Rauber 11/13/06-12/22/06

Rotation 6 Minh-Thu Nguyen 01/08/07-02/16/07
Sarah Shore 01/08/07-02/16/07

UOC Practice resident Kelli Gibson 01/02/07-01/31/07

Rotation 7 Kai Davids 02/19/07-03/30/07
Christien Paynter 02/19/07-03/30/07

Non-traditional Khaloud Alsilmi 02/16/07-03/30/07

Rotation 8 Kevin Fanciulli 04/02/07-05/11/07
Eugene Medley 04/02/07-05/11/07

VA Resident Michael Faithe 05/01/07-05/30/07

Summer 2007

Neurology Fellow Sarah Johnson 06/16/07-06/16/08

Fall 2007

Rotation 4 Natasha Hounshell 10/01/07-11/09/07
Jessica Trujillo 10/01/07-11/09/07

Non-traditional Debbie Rodriguez 10/02/07-12/15/07

Rotation 5 Heather Pentecost 11/09/07-12/21/07
Baochau (Lisa) Nguyen 11/09/07-12/21/07

Spring 2008

Rotation 6 Kimberly Strube 01/06/08-02/15/08
Timothy Leung 01/06/08-02/15/08

Rotation 7 Becky Hoss 02/18/08-03/28/08
Ashley LeTourneau 02/18/08-03/28/08
Jeri Sandbach 02/18/08-03/28/08

Non-traditional Julia Su 01/06/08-02/15/08

Rotation 8 Kristen Lewis 03/31/08-05/09/08
Gloria Mendez-Greene 03/31/08-05/09/08

Summer 2008

Neurology Fellow Sarah Johnson 06/16/08-current

Work Study Student Brooke Glasmann 07/01/08-current

Fall 2008

Rotation 4 Julie Bohm 09/29/08-11/07/08
Alison Schomerus 09/29/08-11/07/08

Rotation 5 Duke Cheney 11/10/08-12/19/08
Michael Egeberg 11/10/08-12/19/08

Spring 2009

Rotation 6 Samuel Addae 01/05/09-02/13/09
Dominique Minjarez 01/05/09-02/13/09

Rotation 7 Stephanie Chonka 02/16/09-03/27/09
Brittany Hanselin 02/16/09-03/27/09

Rotation 8 Kevin Stellish 03/30/09-05/08/09
Alyssa Walker 03/30/09-05/08/09

Summer 2009

Neurology Fellow Michael Egeberg 07/01/09-06/30/11

Fall 2009

Rotation 4 Xiao-Meng Li 09/28/09-11/06/09
May Wong 09/28/09-10/30/09

Rotation 5 KimDao Dang 11/09/09-12/18/09
Brenda Singer 11/09/09-12/18/09

Spring 2010

Rotation 6 Mark Alfonso 01/04/10-02/12/09
Dain Clark 01/04/10-02/12/09

Rotation 7 Olga Artyomenko 02/15/10-03/26/10
Lina Chau 02/15/10-03/26/10

Rotation 8 Inessa Gershteyn 03/29/10-05/07/10
Kelli Frame 03/29/10-05/07/10

Summer 2010

Neurology Fellow Michael Egeberg 07/01/09-06/30/11

Fall 2010

Rotation 4 Nicholas Bennett 10/04/10-11/12/10
Doris Leung 10/04/10-11/12/10

Rotation 5 Tina Thai 11/15/10-12/24/10
Jiyoung Min 11/15/10-12/24/10

Spring 2011

Rotation 6 Michelle Benjamin 01/10/11-02/18/11
Jeffrey Clark 01/10/11-02/18/11

Rotation 7 Shaun McDonald 02/21/11-04/01/11
Rebecca Flores 02/21/11-04/01/11

Rotation 8 Brianna Toppel 04/04/11-05/13/11

Summer 2011

Neurology Fellow Jeffrey Clark 07/06/11-07/01/12

Fall 2011

Rotation 4 Felice Lucero 10/03/11-11/11/11
Emma Ross

Spring 2012

Rotation 6 Thuy Thi Nguyen 01/09/12-02/17/12
Larisa Tarasova

Rotation 7 James Delk 02/20/12-03/30/12
Stacy Haney

Rotation 8 Zachary Smith 04/02/12-05/11/12
Tom Vang

Summer 2012

Rotation 2 Eric Edwards 07/09/12-08/17/12
(France) Jean-Xavier Peyronnet 07/30/12-08/17/12

Neurology Fellow Caleb Oh 07/06/12-07/01/13

Fall 2012

Rotation 4 Lisa Hong 10/01/12-11/09/12
Karrine Roberts

Spring 2013

Rotation 6 Andrew Webb 01/07/13-02/15/13
Jodi Dudley

Rotation 7 John Shin 02/18/13-03/29/13
Jennifer Rother

Rotation 8 Aaron Hales 04/02/13-05/10/13
Sheri Irvine 04/02/13-05/10/13

Fall 2013

Neurology Fellow Pei Shieen Wong 09/01/2013-10/1/2015

Rotation 2 Christina Payne 04/01/13-05/10/13

Rotation 4 A. Christina Franklin 07/08/13-08/16/13
(NTPD)

Rotation 4 Sean Ottamakorn 09/30/13-11/08/13
Steven Merrill (honors) 09/30/13-11/08/13

Rotation 5 Rachael Riddell (honors) 11/11/13-12/20/13

Spring 2014

Rotation 6 Douglas Clark 01/06/14-
John Kapisarov 01/06/14

Rotation 7 Steven Merrill 03/03/14-04/11/2014
Don Nguyen 03/03/14-04/11/2014

Psychiatry 2nd Year Resident

Anne Eudy 04/01/2014-05/01/2014
Noah (Nevo) Ofir 05/01/2014-05/30/2014

Rotation 8 Jenna Katz 04/14/2014-05/23/2014

Kelsey Noffsinger 04/14/2014-05/23/2014

Summer 2014 Crystal Ho 06/09/2014-07/18/2014
CU downtown campus

Fall 2014

Rotation 4 Caitlin Butler 09/29/2014-11/07/2014
Colby Johnson 09/29/2014-11/07/2014

Rotation 5 Kristina Debattista 11/10/2014-12/19/2014
Thanh-Nhung Nguyen 11/10/2014-12/19/2014

Rotation 6
Advanced IPPE

Leah Armbrecht 01/05/2015-01/13/2015
Joshua Min 01/05/2015-01/13/2015

Psychiatry 2nd Year Resident

Kim Seratt 01/12/2015-02/06/2015

Numerous IPPE students/ P1 Shadowing students/ P4 Portfolio students

PHRD 8100 P4 Portfolio 11/9/12-03/20/13
Matthew Johnson P4
Clarissa Manzi P4

IPPE Spring PHRD 5005-5905 Faculty Shadowing 01/22/13-05/18/13
Taylor Alford P1
Driss Gaieb P1
Jacqueline Lunt P1
Jessica Oneal P1

IPPE Spring PHRD 6350 Health-System 01/22/13-05/18/13
Kristina DeBattista P2
Emily Gomez P2
Jordan Reese P2

IPPE Spring PHRD 7350 Health-System 01/22/13-05/18/13
Jenna Katz P3

IPPE Spring PHRD 5005-5905 Faculty Shadowing 08/19/13-12/13/13
Jessica Ashenfelter P1

Dana NG P1
Laura Pultorak P1
Christina Ta P1
Amanda Ward P1

IPPE Fall PHRD 7300 Health-System 08/19/13-12/13/13
Emily Gomez P# 2

Advanced IPPE Spring 2015
Leah Armbrecht
Joshua Min

IPPE 2014
Catherine Thai
Emily Gomez

IPPE Spring 2015
Matthew Makelky
Labdhi Parikh

C. Continuing Education (1 hour and 2 hour CEUs awarded)

Local

CPS – Advances in the Treatment of Epilepsy. Beaver Creek, Colorado
1/2014. (2 hr CE).

***Neurology Grand Rounds University of Colorado Anschutz Medical
Campus. Putting the Action in Drug Interaction: And Updates in
Neuropharmacy. July 16, 2014. (1 hr CE)***

Spectrums – Care in MS.
Chicago, Denver, Texas, Boston 2014. (4 hour CE)

CPS – Updates on MS and Epilepsy Drug Therapies. August 2014. (2 hr
CE)

Neurology Grand Rounds University of Colorado Anschutz Medical
Campus. Movement Disorders, Motivation Interviewing. May 1, 2013.
(1.5 hr CE)

ASIM – updates in MS. Boulder Colorado. May 2014.

AMCP – Updates in MS. Tampa, Florida. June 2014.

Neurology Grand Rounds University of Colorado Anschutz Medical Campus. Status Epilepticus. February 2013. (1.5 hr CE)

When Miracle Drugs Fail. John Carpenter, Jacquelyn Bainbridge. Skaggs School of Pharmacy and Pharmaceutical Sciences. Aurora, Co. November 2, 2012. (2 HR CE).

“Neurology Update- AEDs and Epilepsy. UCH Pharmacy Grand Rounds Michael Faithe and Jacquelyn Bainbridge. UCH, Aurora, Colorado. November 18 and November 24, 2012. (1 hour)

“Neurology Update- AEDs and Epilepsy. UCH Pharmacy Grand Rounds Michael Faithe and Jacquelyn Bainbridge. UCH, Aurora, Colorado. November 18 and November 24, 2009. (1 hour)

“Clinical Pearls in the Management of Parkinson’s Disease”. Colorado Pharmacist Society. Denver, CO. October 5, 2007.

“Epilepsy Treatment, Annual Review Course”. University of Colorado Health Sciences Center. Denver Country Club, Denver, CO. September 17, 2005.

“New Developments in the Prevention and Treatment of Migraine Headache”. Colorado Pharmacists Society (CPS). February 23, 2005.

“Disease Modifying Drugs in Multiple Sclerosis”. CPS Aurora, CO. October 21, 2004.

“Evidence Based Treatment of Epilepsy”. American Academy of Colleges of Pharmacy (AACP). National Conference Salt Lake City, UT. July 14, 2004. (CE)

“Treating Epilepsy”. Colorado Nursing Society. Aurora, CO. September 23, 2004.

“The Treatment of Multiple Sclerosis”. Preceptors & Friends Fall Educational Conference. September 18, 2004.

“Pharmacotherapy of AEDs”. UCH Department of Pharmacy. Denver, CO. September 1, 2004.

“The Clinical Use of Antiepileptic Drugs”. Colorado Nursing Society. Denver, CO. April 14, 2003.

“The Clinical Use of Antiepileptic Drugs”. CPS. Denver, CO.
April 9, 2003.

“The Clinical Use of Antiepileptic Drugs”. Neurosciences Nurses
Association. University of Colorado Health Sciences Center, Denver, CO.
February 24, 2003.

“Pathophysiology and Treatment of Multiple Sclerosis and Epilepsy”.
Nurse Practitioner Program Planned Parenthood. February 19, 2003.

“The Challenges of Patient Counseling and Adherence”. Sponsored by
Postgraduate Institute for Medicine. December 5, 2002.

“The Pathophysiology of Multiple Sclerosis (MS) and Immune
Modulating Therapies”. Denver, CO. August 23, 2002.

“Antiepileptic drugs (AEDs) and their use in epilepsy”. Denver, CO.
July 15, 2002.

Depacon® & Depakote® (Divalproex Sodium) New Options In The
Treatment for Seizures, Headache & Bipolar Agitation/Aggression.
Denver, CO. May 2, 2002.

“Depacon® rapid infusion”. Denver Veterans Administration Medical
Center (DVAMC). Denver, CO. February 27, 2002.

“Multiple Sclerosis”. Colorado Pharmacists Society First Annual
Convention. Holiday Inn DIA, Denver, CO. August 23, 2001.

“How to Pharmaceutically Care for the Patient with Epilepsy”.
Neurologic Nurses Association. October 2, 2000.

“Update on Keppra®”. Denver VA Medical Center, Denver, CO.
September 18, 2000.

“An Update on Antiepileptic Drugs for Nurses”. August 29, 2000.

“The Medical Management of Headache”. National Headache Society
Meeting. Denver, CO. June 24, 2000.

“Update on Keppra®”. Pharmacy Department at University Hospital
Denver, CO. May 24, 2000.

“Update on Depacon®”. University of Colorado Department of
Pharmacy, Denver, CO. February, 24, 2000.

“Update on Depacon®”. Veterans Administration Pharmacy Department. January 12, 1999.

“Update on Depacon®”. Temple Buell Theater, Denver, CO. October 23, 1999.

“Parkinson’s disease, national journal club”. May 3 1999.

“Fosphenytoin and epilepsy review”. University of Colorado. Denver, CO. March 9, 1999.

“ Parkinson’s disease: An Update”. Academy of Consultant Pharmacists. (CPHA) January 6, 1999.

“A review of Parkinson’s disease”. Colorado Society of Hospital Pharmacists. (CSHP) November 24, 1998.

“An update of Dementia”. DAPA. September 15, 1998.

“A review of Old and New Antiepileptic Drugs. CSHP. 1998.

“New Antiepileptic Drugs”. CSHP and CPHA. 1998.

“New Drugs for the Treatment of Epilepsy”. University of Colorado School of Pharmacy. Denver, CO. November 24, 1997.

Treatment of Epilepsy “Topiramate”. University Hospital Department of Pharmacy. Denver, CO. October 23, 1997.

“Practical Applications of Neuropharmacological Interventions in the Treatment of Epilepsy.” Denver, CO. January 1996.

“Diphenhydramine in Conjunction with Felbamate for Insomnia.” University of Colorado, School of Pharmacy. Denver, CO. March 15, 1995.

“Assessment of Antiepileptic Drug Treatment Failure in Complex Partial Seizures.” University of Colorado, School of Pharmacy. Denver, CO. October 5, 1994.

“CPR and COR-ZERO Response.” CSHP, Annual Meeting. Denver, CO. 1992.

State

“Updates on Multiple Sclerosis and Epilepsy Drug Therapies”. CPS. (1 hr CE) Regis University. August 8, 2014

“The Spectrum of MS: Providing Comprehensive Primary and Specialty Patient Care Through Enhanced Collaboration”. ASIM, NPA, Advanced Studies in Pharmacy, The Consortium of Multiple Sclerosis Centers”. Physicians, Pharmacists, Nurse Practitioners. (3.75 hr CE). Steering committee and lecturer. June 14, 2014.

“What’s New in Neurology Medications: Neuroprotection: Parkinson’s disease, Multiple Sclerosis and Headache”. Nurse Practitioner Program. Keystone, CO. July 10, 2008.

“New Pharmacotherapy of Parkinson’s Disease.” CPS, 15th Annual Winter Continuing Education Seminar. Aspen, CO. 2007.

“New Developments in the Prevention and Treatment of Migraine Headache.” CPS. February 23, 2005.

“Top 10 Articles in The Last 3 Years on the Pharmacology of AEDs.” Epilepsy Syndromes and Special Populations. 3rd Biennial Rocky Mountain Epilepsy Conference. Breckenridge, CO. January 14, 2005.

“Review of drug-drug, drug-food, drug-herbal interactions.” Epilepsy Syndromes and Special Populations. 3rd Biennial Rocky Mountain Epilepsy Conference. January 14, 2005. Breckenridge, CO.

“Migraine Therapies”. Fort Carson Army Base, Colorado Springs, CO. April 16, 2004.

“AEDs in Clinical Practice”. Centennial Area Health Education Center (AHEC) in Grand Junction, CO. February 22, 2004.

“The Clinical Use of Antiepileptic Drugs”. CPS. Colorado Springs, CO. May 1, 2003.

“Rocky Mountain Epilepsy Research and Clinical Conference” Neuroprotection and Clinical Epileptology. Breckenridge, CO. January 9-12, 2003.

“The treatment of Multiple Sclerosis”. Colorado Springs, Neurological Association, P.C. Colorado Springs, CO. September 4, 2002.

“Polypharmacy and Antiepileptic Treatment in the DD Population”. Continuing education for nurses and health care providers in rural

Colorado. Lafayette, CO. June 28, 2002.

“New Antiepileptic Drugs (AEDs) in Clinical Practice. AHEC in Greeley. May 18, 2002.

“Antiepileptic Drugs and Herbal Products”. Epilepsy Foundation of Colorado Meeting in Grand Junction, CO. October 20, 2001.

“Uses of Antiepileptic Drugs”. State Hospital, Pueblo, CO. September 27, 2000.

“Migraine – medical treatment”. Alamosa, CO. March 29, 2000.

“The Medical Management of Headache”. University of Oklahoma, Norman, OK. May 18, 2000.

“The Medical Management of Seizures”. Medical Grand Rounds in Colorado Springs, CO. May 3, 2000.

National

Spectrums – Care in MS.
Chicago, Denver, Texas, Boston 2014. (4 hour CE)

ASIM – updates in MS. Boulder Colorado. May 2014.

AMCP – Updates in MS. Tampa, Florida. June 2014.

“The Spectrum of MS: Providing Comprehensive Primary and Specialty Patient Care Through Enhanced Collaboration”. ASIM, NPA, Advanced Studies in Pharmacy, The Consortium of Multiple Sclerosis Centers”. Physicians, Pharmacists, Nurse Practitioners. (3.75 hr CE). Steering committee and lecturer. May 10, 2014 Scottsdale, May 17, 2014 Chicago, June 7, 2014 NYC.

“Advances in the Management of MS”. Live and Webinar. (1.5 hr CE). June 11, June 17 and July 10, 2014.

“Therapeutic Updates, Best Practices, and Barriers to Care in the Presentation and Treatment of Multiple Sclerosis”. Webinar CME (CE) March 2013.

“2013 Updates in Therapeutics. The Pharmacotherapy Preparatory Course. Epilepsy and Headache/Migraine.” ACCP Ambulatory Care Prep Course. Reno, NV. March, 2013 (1 hour CE)

“Therapeutic Updates, Best Practices, and Barriers to Care in the Prevention and Treatment of Multiple Sclerosis”. ScientiaCME, Webinar. (CE). March, 1, 2013.

“Helping Patients Navigate the Ups and Downs of Multiple Sclerosis”. APhA. Los Angeles, CA. March 3, 2013. (2 hour CE) CO-Chaired event.

“Evaluating New & Emerging Therapies to Improve Patient Outcomes through the Continuum of Care”. American Health Resources. Hartford CT. (2 hr CE) September 22, 2012

“Evaluating New & Emerging Therapies to Improve Patient Outcomes through the Continuum of Care”. American Health Resources. Newton MA. (2 hr CE) September 15, 2012

“Multiple Sclerosis: Managing the Whole Patient.” APhA 2012. New Orleans, LA. March 12, 2012. (2 hour CE)

“MS Treatment in the 21st Century”. ASIM. Boulder CO. June, 2012. (CE 2 hours)

“2012 Updates in Therapeutics. The Pharmacotherapy Preparatory Course. Epilepsy and Headache/Migraine.” ACCP 2011. Reno, NV. 2012 (1 hour CE)

“Actionable Insights to the Evolving Management of MS: Important Considerations in Improving Outcomes”. “Clinically Isolated Syndrome: Why to Treat? Chair of the program. ASIM 2011. July 28, 2011 (1.5 hour CE) repeated 4 times

Chen JJ. Drug therapy for Parkinson's Disease and adherence to therapy. *Towards Improved Adherence In Parkinson's Disease Therapy: The Key Role of Pharmacists*. Available at <http://www.powerpak.com/course/preamble/107857>. Published October 3, 2011. I chaired this and assisted with this project.

“Drug Therapy for Advanced Parkinson’s Disease and Adherence to Therapy”. October, 2011. (1.5 hours CE) and web publication.

“2011 Updates in Therapeutics. The Pharmacotherapy Preparatory Course. Epilepsy and Headache/Migraine.” ACCP 2011. Columbus, OH. April 9, 2011 (1 hour CE)

“Multiple Sclerosis and the Disease-Modifying Therapies.” APhA 2011. Seattle, WA. March 26, 2011. (2 hour CE)

“Emerging Challenges on the Therapeutic Landscape of Multiple Sclerosis. The Managed Care Pharmacy and Medical Directors Perspective. CMEducation Resources, LLC. Three Cities, New York October 23, 2010, Atlanta October 30, 2010, Boston November 13, 2010. (3.5 hours)

“Brand vs. Generic Bioequivalence: Is there a Difference in Antiepileptic Drug (AED) Therapy in Seniors?” Epilepsy Foundation of America. ASCP conference. Orlando, Florida. November 11, 2010. (1.5 hours)

“Pharmacists’ Practical Guide to the Management and Treatment of Symptoms of Multiple Sclerosis. Projects In Knowledge. AMCP Educational Conference. St. Louis, Missouri. October 17, 2010. (1.5 hours)

“Managing Chronic Noncancer Pain With Opioids: A Case Approach for the Pharmacist”. CESolution. July 15, 2010. (1.5 hours)

“The Evolving Paradigms in Multiple Sclerosis: Focus on Early Identification and Treatment Initiation”. Four Webcast series presented live. August 10, August 17, August 31, and September 14, 2010. (1.5 hours each).

“The Evolving Paradigms in Multiple Sclerosis: Focus on Early Identification and Treatment Initiation”. Houston, TX. May 6, 2010. (1 hour)

“Brand vs. Generic, Is There a Difference for Antiepileptic Drugs”? ACCP Spring Practice and Research Forum. Charlotte, North Carolina. April 24, 2010. (1 hour)

“The Pharmacologic Management of Epilepsy”. University of Arizona. Grand Rounds Department of Neurology. Neurologists, Neurosurgeons, Residents, Nurses, Ph.D.’s. Tucson, AZ. October 30, 2009. (1 hour)

“Emerging Therapies in Epilepsy”. New Mexico Pharmacists Association. Albuquerque, NM. February 1, 2009. (1 hour)

“What’s New In Neurology Medications: Neuroprotection: Parkinson’s disease, Multiple Sclerosis, Epilepsy, and Headache.” 33rd National Primary care Nurse Practitioner Symposium. Keystone, CO. July 11, 2008 (1.5 hours)

I organized, grant funded this project and moderated the session. 3rd annual epilepsy and neurology update meeting. November 10, 2007. (5 CEU’s).

“Clinical Pearls in the Management of Parkinson’s Disease”. Colorado Pharmacist Society. Phoenix, AZ. October 4, 2007.

Parkinson’s disease. Corporate Meeting Solutions. Phoenix, AZ. September, 2007.

“A Review of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AEDs”. MedAssets Supply Chain Systems. CE Teleconference. March 13, 2007.

Neuropharmacology of Antiepileptic Drugs. AES. 2007.

“Disease Modifying Drugs in Multiple Sclerosis (MS)”. University of Colorado at Denver and the Health Sciences Center, Denver, CO. 2007.

“Using Pathophysiology to Optimize Therapeutic Approach”. American Managed Care Pharmacists (AMCP). Chicago, IL. October 4, 2006.

“Treatment Optimization in Practice: Multiple Sclerosis”. AMCP. Chicago, IL. October 4, 2006.

“Treatment Optimization in Other Chronic Diseases”. AMCP. Chicago, IL. October 4, 2006.

“The Use of the Vagus Nerve Stimulation in Seizure Disorders”. American College of Clinical Pharmacy (ACCP). October, 2006.

“Using the Newer AED’s Compared to the Older AED’s”. Fort Bliss Army Base, EL Paso, TX. July 28, 2006.

“Using the Newer AED’s Compared to the Older AED’s”. Fort Bliss Army Base, EL Paso, TX. July 27, 2006.

Neuropharmacology of Antiepileptic Drugs. American Epilepsy Society. 2006.

“New Antiepileptic Drugs (AEDs) in Clinical Practice”. Florida Society of Health Systems Pharmacists (FSHP). Jacksonville, FL. June 16, 2005.

“When the Body Attacks: An Update on the Treatment of Immune Mediated Diseases”. National through CD-ROM and Internet Presentation. January 2005.

Neuropharmacology of Antiepileptic Drugs. AES. 2005.

“When the Body Attacks: An Update on the Treatment of Immune Mediated Diseases”. National through CD-ROM and Internet Presentation. December 2005.

“Pharmacology of Multiple Sclerosis and Disease Modifying Drugs”. Pharmacists. 2nd Annual Neuro/Psych Symposium. Temecula, CA. October 16, 2004.

“Evidence Based Treatment of Epilepsy”. **Plenary Session**. American Academy of Colleges of Pharmacy (ACCP). National Conference Salt Lake City, UT. July 14, 2004.

“New Onset Seizures in the Elderly”. AES. Boston, MA. December 5, 2003.

“Advances in Multiple Sclerosis”. Western University of Health Sciences College. Temecula, CA. November 23, 2003.

“The Use of IV Dexamethasone In Place of IV Methylprednisolone”. ACCP. Atlanta, GA. November 2003.

“The Use of Preventatives in the Treatment of Migraine”. Moderator and Speaker. ACCP. Atlanta, GA. November 2003.

“Pathophysiology and Immune Therapy in MS”. Illinois Pharmacy Society. Chicago, IL. October 2003.

“Medication adherence in chronic disorders”. Portland, OR. January 21, 2003.

“The Challenges of Patient Counseling and Adherence”. Seattle, WA. January 14, 2003.

“The Challenges of Patient Counseling and Adherence”. Las Vegas, NV. December 14, 2002.

“The Pathophysiology of Multiple Sclerosis (MS) and Immune Modulating Therapies”. American Society of Health System Pharmacists (ASHP) midyear meeting. Atlanta, GA. December 11, 2002.

“The Challenges of Patient Counseling and Adherence”. Salt Lake City, UT. November 16, 2002.

“Medication adherence in Migraine, Depression and Herpes infections”. . Phoenix, AZ. October 29, 2002. (CE)

“The Pathophysiology of Multiple Sclerosis (MS) and Immune Modulating Therapies”. Austin, TX. October 4-6, 2002. (CE)

“Antiepileptic Drugs (AEDs) in Clinical Practice”. California Employee Pharmacist Association (CEPA). San Diego, CA. May 2, 2002. (CE)

“Antiepileptic Drugs (AEDs) in Clinical Practice”. CEPA. New Port Beach, CA. April 24, 2002. (CE)

“First Line Treatment of Migraine: Analgesics or Triptans?”. ACCP focus session, Annual meeting, Tampa, FL. October 22, 2001. (CE)

Parkinson’s disease (PD) The “Shaking Palsy” Syndrome. New Mexico Pharmaceutical Association. Albuquerque, NM. June 23, 2001. (CE)

“Antiepileptic Drug Choice Based on Mechanism of Action, Drug-Drug Interaction Profile and the Patient”. Park City, UT. November 11, 2000. (CE)

“Herbal Therapy and Epilepsy”. National Epilepsy Meeting. Atlanta, GA. August 11, 2000. (CE)

“Update on Antiepileptic Drugs”. Florida. July 15, 2000. (CE)

"Antiepileptic Drugs: A Review". Grand Rounds. Long Beach, CA. June 28, 2000. (CE)

"Update on Keppra ". Northern California Medi-Cal Continuing Education Program. Stockton, CA. June 7, 2000. (CE)

“Practical Applications of Building a Rotating Specialty Residency.” ACCP meeting, Nashville, TN. 1996. (CE)

“The Medical Management of Migraine”. The University of Oklahoma Department of Pharmacy, School of Pharmacy, and Medical House Staff. Oklahoma City, OK. May 8, 2000. (CE)

International

“HMDP Visiting Experts FY 2015 Ministry of Health Singapore” Start date November 16, 2015- November 25, 2015. Singapore (40 hours of CE). (CE)

“Novel Therapies for Brain Disease in Those Patients that are going Downhill Fast”. Winter Conference on Brain Research. Big Sky,

Montana 1/29/2015. (2 hr CE).

“No More Seizures – Brand vs. Generic Bioequivalence”. American Academy of Neurology. Honolulu, HI. Epilepsy Foundation of America. April 9-16, 2010. (CE)

“Experimental Methods to Guide the use of Combination AED Therapy”. American Epilepsy Society (AES) – Neuropharmacology -Special Interest Group (SIG) Co-coordinated and Moderated session. December 6, 2010

“Status Epilepticus”. American Epilepsy Society (AES) – Neuropharmacology - Special Interest Group (SIG) Co-coordinated and Moderated session. December 4, 2009

“Fact or Fiction” Brand AEDs vs Generic AEDs. **Plenary Parallel Session.** The American Epilepsy Society (AES). Philadelphia, PA. November 30, 2007.

Invited to 2nd Eilat International Educational Course: Pharmacological Treatment of Epilepsy. Eilat, Israel.
Small group instruction on pharmacokinetics. September 2-9, 2007. (CE)

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. August 7, 2007.

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. July 31, 2007.

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. July 24, 2007.

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. July 17, 2007.

D. Courses Providing Certificates

Instructor, Basic Life Support, 1991 – present

VII. CLINICAL/CONSULTING ACTIVITIES

HMDP Visiting Expert FY2015. Ministry of Health Singapore. November 16, 2015-November 25, 2015.

COMIRB executive committee. Credentialing with Association for the Accreditation of the Human Research Protection Programs (AAHRPP) interview

on February 16th, 2012. Provides comprehensive protection to research participants.

Corporate Advisory Committee (CAC) of American Epilepsy Society February 7, 2012- present

Achieving Seizure Control, Embracing New Directions (ASCEND) working group November 4, 5, 2010

The University of Tennessee College of Pharmacy and ASiM.

ProCE, Inc., 2009, 2010, 2011, 2012, 2013 –Developed material and slide deck and patient cases

The University of Tennessee College of Pharmacy and ASiM.

ProCE, Inc., ECTRIMS MS Meeting 2008 - Developed material and slide deck

Postgraduate Institute of Medicine Education (PIM)

Micromedex, Inc.

Tri-County Health Department, Denver, Colorado

Mediplex

Colorado Mental Health Institute

Psychiatry and Neurology, School of Medicine

School of Dentistry

Department of Neurosurgery, School of Medicine

VIII. HONORS

Skaggs School of Pharmacy and Pharmaceutical Sciences P2 Professor of the Year. 2010, 2011, 2012, 2013.

University of Colorado Denver, School of Pharmacy P2 Professor of the Year, 2008

Preceptor of the Year, School of Pharmacy. University of Colorado Health Sciences Center, 2005

Fellow American College of Clinical Pharmacy, 2004

Preceptor of the Year, School of Pharmacy. University of Colorado Health Sciences Center, 2003

Rho Chi National Pharmaceutical Honor Society, 1995

Pharmacist of Year, University of Colorado Hospital, 1992

Masonic Temple Academic Scholarship, 1986

Youngstown State University, Dean's List

Ohio Northern University, Dean's List

Outstanding recruitment VA Study # 428 2002

Outstanding recruitment VA Study # 428 2001

Outstanding recruitment VA Study # 428 1999

Outstanding recruitment VA Study # 428 1998

Outstanding service Colorado Multiple Institutional Review Board 2001

“Fact or Fiction” Brand AEDs vs Generic AEDs. **Plenary Parallel Session.**

AES. Philadelphia, PA. November 30, 2007. (CE)

“Evidence Based Treatment of Epilepsy”. **Plenary Session**. AACP National Conference. Salt Lake City, UT. July 14, 2004. (CE)

IX. SPEAKING ENGAGEMENTS

A. Local

Parkinson Disease and Treatment. E3 Conference – Educate, Empower, Energize. Sponsored by Parkinson Association of the Rockies (PAR). DTC Marriott. October 9, 2015.

Parkinson Disease & Medications. February 2, 2015.

“ Grand Rounds Neurology Department – Pharmacokinetics”. July, 2014.

Multiple Sclerosis and Parkinson Disease. Physical Therapy Department. February, 2014.

The Refractory Brain: Designing Drugs to Treat Challenging Disorders for the Central Nervous System. Genes to Drugs: The evolution of the effective treatments of Fragile X Syndrome and associated comorbid disorders. CU Homecoming at the Skaggs School of Pharmacy and Pharmaceutical Sciences. October 2013. (1 hr CE)

Neurology Grand Rounds University of Colorado Anschutz Medical Campus. Movement Disorders, Motivation Interviewing. May 1, 2013. (1.5 hr CE)

Multiple Sclerosis and Parkinson Disease. Physical Therapy Department. January, 2013.

Neurology Grand Rounds University of Colorado Anschutz Medical Campus. Antiepileptic Drugs. September, 2013.

Local Workshop for Pharmacists. Achieving Seizure Control embracing New Directions. Lutheran Hospital. March 12, 2013.

Local Workshop for Pharmacists. Achieving Seizure Control embracing New Directions. March 7, 2013.

Neurology Grand Rounds University of Colorado Anschutz Medical Campus. Status Epilepticus. February 2013. (1.5 hr CE)

Willis-Ekbom Disease (WED) Previously Restless Legs Syndrome (RLS) Boulder Colorado. January 31, 2013.

When Miracle Drugs Fail. John Carpenter, Jacquelyn Bainbridge. Skaggs School of Pharmacy and Pharmaceutical Sciences. Aurora, Co. November 2, 2012. (2 HR CE).

Epilepsy Patient Advocate Presentation. Spring Hill Suites by Marriott – Denver Aurora Fitzsimons, Aurora, CO. September 18th, 2012.

Epilepsy Patient Advocate Presentation. Denver Heath Medical Center. Denver, CO. July 31st, 2012.

“AED Drug-Drug Interactions”. Ocean Prime. April 2011.

“MS Treatments”. Barolo Grill. Physicians, Nurse Practitioners, Pharmacists. March, 2011.

“To Pharmacists, A Discussion on the Antiepileptic Drug Vimpat and Other AEDs”. Penrose – St. Francis, Colorado Springs, CO. February 18, 2011.

“An Interactive Discussion on the Antiepileptic Drug, Vimpat.” Del Frisco. December 13, 2010.

“Logical Polypharmacy: An AED Review”. Barolo Grille. Neuropharmacy Journal Club. Supported by UCB Pharma. April 14th, 2010.

“Neurology Update- AEDs and Epilepsy. UCH Pharmacy Grand Rounds Michael Faithe and Jacquelyn Bainbridge. UCH, Aurora, Colorado. November 18 and November 24, 2009. (CE)

“RLS:Update From Scientific Meeting October 2008: Advances of Research Toward a Cure”. Restless leggs syndrome support group at National Jewish Hospital. November 15, 2008.

“The Implications of Using the Newer Anti-epileptic Drugs (AEDs) Compared to the Older AEDs for Dentists”. University of Colorado Denver, School of Dentistry. Contact person Rob Berg. October 1, 2008.

“Implications of Using the Newer Anti-epileptic Drugs (AEDs) Compared to the Older AEDs and Generic Substitution”. Grand-Rounds Neurosurgery University of Colorado Denver. Denver, CO. June 17, 2008.

“The Treatment of Restless Legs Syndrome and Generic Substitution”.

National Jewish Medical Center. Denver, CO. May 17, 2008.

“Clinical Pearls in the Management of Parkinson’s Disease”. Denver, CO. October 5, 2007. (CE)

“Advances in Epilepsy Diagnosis and Treatment”. Denver, CO. October 24, 2006.

“A Review of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AE’s in the Acute Care Arena”. Sponsored by UCB Pharma. Barolo Grill, Denver, CO. October 24, 2006.

“A Review of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AEDs in the Acute Care Setting”. Grand Rounds, University of Colorado Health Sciences Center, Denver, CO. September 19, 2006.

“A Review of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AEDs”. University of Colorado Health Sciences Center, Denver, CO. June 8, 2006.

“ Implications of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AEDs”. University of Colorado Health Sciences Center. Sponsored by UCB Pharma. Campo de Fiore, Denver, CO. May 12, 2006.

“ Newer Anti-Epileptic Drugs (AEDs) Compared to the Older AEDs: Can We Continue to Justify Using the Older AEDs”? Kindred Pharmacy. Sponsored by UCB Pharma. Denver, CO. March, 2006.

“Restless Legs Syndrome”. Restless Legs Society Support Group. National Jewish Medical Center, Denver, CO. February 25, 2006.

“Practical Applications of Newer AEDs Compared to the Older AEDs: Can We Continue to Justify Using Older AEDs?”. University of Colorado Hospital. Sponsored by UCB Pharma. November 11, 2005.

“Epilepsy Treatment, Annual Review Course”. University of Colorado Health Sciences Center. Denver Country Club, Denver, CO. September 17, 2005.

“The Treatment of Migraine”. Neurological Society. Denver, CO. May 25, 2005.

“The Pharmacological Management of Migraines”. Denver, CO. April 29, 2005.

“Pathophysiology and Acute Treatment of Migraine”. Physicians and other health care practitioners. Denver, CO. April 28, 2005.

“Serious Adverse Effects”. Novartis Preceptorship, Novartis Sales Force. Denver, CO. March 17, 2005.

“Mechanisms of Action and Neuromodulation by Antiepileptic Drugs”. Novartis Preceptorship, Novartis Sales Force. Denver, CO. March 17, 2005.

“Antiepileptic Drug Kinetics & Interactions”. Novartis Preceptorship, Novartis Sales Force. Denver, CO. March 16, 2005.

“Efficacy of AEDs: Old & New. Novartis Preceptorship, Novartis Sales Force. Denver, CO. March 16, 2005.

“Common Drug, Food, & Herbal Interactions with Antiepileptic Drugs (AEDs) & Other Neurologic Agents. Women in Neurology. March 5, 2005.

“New Developments in the Prevention and Treatment of Migraine Headache”. Colorado Pharmacists Society. February 23, 2005. (CE)

“What’s New in Antiepileptic Drug Pharmacology and Devices”. Denver, CO. January 27, 2005.

“Pharmacology of Antiepileptic Drugs Part III”. Neurology Residents. Denver, CO. December 1, 2004.

“Pharmacology of Antiepileptic Drugs and Use in Clinical Practice”. Denver, CO. November 2, 2004.

“Disease Modifying Drugs in Multiple Sclerosis”. CPS. Aurora, CO. October 21, 2004. (CE)

“Pharmacology of Antiepileptic Drugs Part II”. Denver, CO. October 13, 2004.

“Pharmacology of Antiepileptic Drugs Part I”. Denver, CO. September 29, 2004.

“Treating Epilepsy”. Colorado Nursing Society. Aurora, CO. September 23, 2004. (CE)

“The Treatment of Multiple Sclerosis”. Preceptors & Friends Fall

Educational Conference. September 18, 2004.

“Pharmacotherapy of AEDs”. UCH Department of Pharmacy. Denver, CO. September 1, 2004. (CE)

“The Pharmacological Management of Migraine”. April 14, 2004.

“New Treatment Modalities for Migraine”. Pfizer Sales Force. January 15, 2004.

“New Treatment for Migraine”. Moderator and Speaker. Physicians, Nurse Practitioners, Physician Assistants, Pharmacists. October 2003.

“The Clinical Use of Antiepileptic Drugs”. Colorado Nursing Society. Denver, CO. April 14, 2003. (CE)

“The Clinical Use of Antiepileptic Drugs”. CPS. Denver, CO. April 9, 2003. (CE)

“The Medical Management of Restless Legs Syndrome”. National Restless Legs Syndrome Society. National Jewish Hospital, Denver, CO. March 22, 2003.

“The Clinical Use of Antiepileptic Drugs”. Neurosciences Nurses Association. University of Colorado Health Sciences Center. Denver, CO. February 24, 2003. (CE)

“Pathophysiology and Treatment of Multiple Sclerosis and Epilepsy”. Nurse Practitioner Program Planned Parenthood. February 19, 2003. (CE)

“The Challenges of Patient Counseling and Adherence”. Sponsored by Postgraduate Institute for Medicine. December 5, 2002. (CE)

“Neuropharmacy lecture to Nurse practitioners”. Lecture covering Multiple Sclerosis and Epilepsy. August 28, 2002.

“The Pathophysiology of Multiple Sclerosis (MS) and Immune Modulating Therapies”. Denver, CO. August 23, 2002. (CE)

“Antiepileptic drugs (AEDs) and their use in epilepsy”. Denver, CO. July 15, 2002. (CE)

Depacon® & Depakote® (Divalproex Sodium) New Options in The Treatment for Seizures, Headache & Bipolar Agitation/Aggression. Denver, CO. May 2, 2002. (CE)

Seizure update. Wheatridge Regional Center. Wheatridge, CO.
March 6, 2002.

“Depacon® rapid infusion”. Denver Veterans Administration Medical
Center (DVAMC). Denver, CO. February 27, 2002. (CE)

“Multiple Sclerosis”. Colorado Pharmacists Society First Annual
Convention. Holiday Inn DIA, Denver, CO. August 23, 2001. (CE)

“Pharmacologic Agents in the Treatment of Epilepsy-Update”. Epilepsy
Foundation of Colorado (EFC) symposium. Four Points Sheraton Hotel,
Denver, CO. April 21, 2001.

Antiepileptic Drug (AED) Pharmacology. The Childrens Hospital,
Denver, CO. March 14, 2001.

“The Medical Management of Peripheral Neuropathy”. Peripheral
Neuropathy Association. February 5, 2001.

“How to Pharmaceutically Care for the Patient with Epilepsy”.
Neurologic Nurses Association. October 2, 2000. (CE)

“Update on Keppra®”. Denver VA Medical Center. Denver, CO.
September 18, 2000. (CE)

“An Update on Antiepileptic Drugs for Nurses”. August 29, 2000. (CE)

“The Medical Management of Headache”. National Headache Society
Meeting. Denver, CO. June 24, 2000. (CE)

“Update on Keppra®”. Pharmacy Department at University Hospital,
Denver, CO. May 24, 2000. (CE)

"Seizure Management". Biennial Rocky Mountain Regional Brain Tumor
Conference, Team Up for Triumph. May 6, 2000.

“Update on Depacon®”. University of Colorado Department of
Pharmacy, Denver, CO. February, 24, 2000. (CE)

“Update on Depacon®”. Veterans Administration Pharmacy Department,
Denver, CO. January 12, 1999. (CE)

“Background and history of the Epilepsy Foundation of Colorado”.
Blacktie event fundraiser. November 1999, 2000 and 2001.

“Update on Depacon®”. Temple Buell Theater, Denver, CO. October 23, 1999. (CE)

“Influenza treatment and update”. Session moderator. July 31, 1999.

“Parkinson’s disease, national journal club”. May 3 1999. (CE)

“Dementia caregivers symposium”. Holiday Inn DIA, Denver, CO. May 3, 1999.

“Neurontin® neurology update”. April 27, 1999.

“Antiepileptic drugs used in the pediatric population”. The Children’s Hospital, Denver, CO. April 27, 1999.

“Round table discussion on epilepsy”. April 27, 1999.

“Parkinson’s disease teleconference”. March 24, 1999.

“Fosphenytoin and epilepsy review”. University of Colorado, Denver, CO. March 9, 1999. (CE)

“Fosphenytoin update”. P&T committee University of Colorado, Denver, CO. February 23, 1999.

“Responsibilities of a board member”. Retreat, Epilepsy Foundation of Colorado. January 16, 1999.

“Parkinson’s Disease: An Update”. CPHA. January 6, 1999. (CE)

“A review of Parkinson’s disease”. Colorado Society of Hospital Pharmacists (CSHP). November 24, 1998. (CE)

“An update of Dementia”. DAPA. September 15, 1998. (CE)

“A review of Old and New Antiepileptic Drugs. CSHP. 1998. (CE)

“New Antiepileptic Drugs”. CSHP and CPHA. 1998. (CE)

“New and Old Antiepileptic Drugs”. Nursing review. University of Colorado Health Sciences Center. Denver, CO. December 1997.

“New Drugs for the Treatment of Epilepsy”. University of Colorado School of Pharmacy. Denver, CO. November 24, 1997. (CE)

Treatment of Epilepsy “Topiramate” University Hospital Department of

Pharmacy. Denver, CO. October 23, 1997. (CE)

Parke-Davis Pharmaceutical representative training provided in antiepileptic drug therapy. Denver, CO. August 4, 1997.

“Practical Applications of Neuropharmacological Interventions in the Treatment of Epilepsy.” Current Status of Epilepsy and Headache symposium for Neurologists and Primary Care physicians, Denver, CO. January 1996. (CE)

“Diphenhydramine in Conjunction with Felbamate for Insomnia.” University of Colorado, School of Pharmacy, Denver, CO. March 15, 1995. (CE)

“A Review of Emergency Medications.” University of Colorado, Denver, CO. October 1994.

“Assessment of Antiepileptic Drug Treatment Failure in Complex Partial Seizures.” University of Colorado, School of Pharmacy, October 5, 1994. (CE)

“CPR and COR-ZERO Response.” CSHP Annual Meeting, Denver, CO. 1992. (CE)

B. State

WED/RLS update. Boulder Colorado. January, 2013.

“Achieving Seizure Control Embracing New Directions” (ASCEND). Penrose St Francis Hospital. May 23, 2013.

“Medications to Treat Alzheimer’s Disease (AD) and Behaviors”. 2009 Annual Symposium for the Alzheimer’s Association. Crowne Plaza DIA. May 8, 2009.

“Boulder Public Library Channel 8 (6 months) TV/Cable for 6 months and DVD – program to the public on RLS”. EnglemanC@boulder.lib.co.us, Chris was the coordinator. May 6, 2009.

“What’s New in Neurology Medications: Neuroprotection: Parkinson’s disease, Multiple Sclerosis and Headache”. Nurse Practitioner Program. Keystone, CO. July 10, 2008. (CE)

“New Pharmacotherapy of Parkinson’s Disease.” Colorado Pharmacists Society (CPS), 15th Annual Winter Continuing Education Seminar,

Aspen, CO. 2007. (CE)

“New Developments in the Prevention and Treatment of Migraine Headache.” CPS. February 23, 2005. (CE)

“Top 10 Articles in The Last 3 Years on the Pharmacology of AEDs.” Epilepsy Syndromes and Special Populations. 3rd Biennial Rocky Mountain Epilepsy Conference. January 14, 2005. Breckenridge, CO. (CE)

“Review of drug-drug, drug-food, drug-herbal interactions.” Epilepsy Syndromes and Special Populations. 3rd Biennial Rocky Mountain Epilepsy Conference. January 14, 2005. Breckenridge, CO. (CE)

“New Pharmacological Management of Migraine”. Physicians Assistants, Fort Carson, Colorado Springs, CO. April 16, 2004. (CE)

“AEDs in Clinical Practice”. Centennial Area Health Education Center (AHEC) in Grand Junction, CO. February 22, 2004.

“The Clinical Use of Antiepileptic Drugs”. CPS. Colorado Springs, CO. May 1, 2003. (CE)

“Rocky Mountain Epilepsy Research and Clinical Conference” Neuroprotection and Clinical Epileptology. Breckenridge, CO. Audience physicians and pharmacists. January 9-12, 2003. (CE)

“Managing Patients with Epilepsy”. Sponsored by the Epilepsy Foundation of Colorado. Grand Junction, CO. November 2, 2002.

“The Treatment of Multiple Sclerosis”. Colorado Springs, Neurological Association, P.C. Colorado Springs, CO. September 4, 2002. (CE)

“Polypharmacy and Antiepileptic Treatment in the DD Population”. Continuing education for nurses and health care providers in rural Colorado. Lafayette, CO. June 28, 2002. (CE)

“New Antiepileptic Drugs (AEDs) in Clinical Practice. Continuing education for pharmacists, physicians, nurses. AHEC in Greeley, CO. May 18, 2002. (CE)

“Depakote®” a review for Physician Assistants. Specifically talked about MIGRAINE. Sponsored by Abbott Pharmaceuticals 10/12/01. Colorado Springs, CO. Government Hospital Associations.

“Antiepileptic Drugs and Herbal Products”. Epilepsy Foundation of Colorado Meeting in Grand Junction, CO. October 20, 2001. (CE)

“Uses of Antiepileptic Drugs”. State Hospital in Pueblo, CO. September 27, 2000. (CE)

“Migraine – medical treatment”. Alamosa, CO. March 29, 2000. (CE)

“The Medical Management of Headache”. University of Oklahoma, Norman, OK. May 18, 2000. (CE)

“The Medical Management of Seizures”. Medical Grand Rounds in Colorado Springs, CO. May 3, 2000. (CE)

“Parkinson’s disease update for patients and caregivers”. Craig, CO. April 29, 1999.

“Antiepileptic drug update”. Colorado Springs, CO. January 21, 1999.

Epilepsy Foundation of Colorado seminar program “Living with Epilepsy” Treatment - New Drugs and Therapies. Grand Junction, CO. October 18, 1997.

“The Treatment of Seizures.” Brain Tumor Support Group, Fort Collins, CO. June 1997.

C. National

“ Restless Legs Syndrome (RLS) and Medications. San Diego CA. Scripts Institute. October 4, 2015.

“ACCP Updates in Therapeutics. The Ambulatory Pharmacotherapy Preparatory Course, Neurology I” (1 hr CE) Chicago, Illinois. April 11, 2015.

“The Evolving Landscape of Multiple Sclerosis (MS): A 2014 Update for Pharmacists”. AMCP. Tampa Florida. (2 hr CE) April, 2014.

“Strategies to Minimize Disease Progression in Multiple Sclerosis”. APhA. (2 hr CE) March 29, 2014.

“The Spectrum of Multiple Sclerosis (MS): Providing Comprehensive Primary and Specialty Patient Care through Enhanced Collaboration”. (2 hr CE) and several webinars. Denver and Chicago. June and July, 2014

“Managing Disease Modifying Therapies in Multiple Sclerosis”. ADURS. Scottsdale, Arizona. (1 hr CE). February, 2014.

“Updates in Neurology”. ACCP. Webinar. (1 hr CE). February, 2014.

“Neurology I”. ACCP Chicago. (1.5 hr CE). April 2014.

“Pioglitazone and Parkinson disease”. Grand Rounds. California. July, 2013.

“Helping Patients Navigate the Ups and Downs of Multiple Sclerosis”. APhA. Chair of the course. Los Angeles, CA. (2 hr CE) .March 1-4, 2013.

“The Clinical Challenges of Multiple Sclerosis: Managed Care and Specialty Pharmacist Perspectives”. CO-Chair of the events. Live presentation and then 4 Webinars. (1.5 hr CE). 2013

“Therapeutic Updates, Best Practices, and Barriers to Care in the Prevention and Treatment of Multiple Sclerosis”. ScientiaCME, Webinar. (CE). March, 1, 2013.

“2013 Updates in Therapeutics. The Pharmacotherapy Preparatory Course. Epilepsy and Headache/Migraine.” ACCP 2013. Reno, NV. 2013 (1 hour CE)

“Therapeutic Updates, Best Practices, and Barriers to Care in the Prevention and Treatment of Multiple Sclerosis”. ScientiaCME, Webinar. (CE). March, 1, 2013.

“Evaluating New & Emerging Therapies to Improve Patient Outcomes through the Continuum of Care”. American Health Resources. Hartford CT. (2 hr CE) September 22, 2012

“Evaluating New & Emerging Therapies to Improve Patient Outcomes through the Continuum of Care”. American Health Resources. Newton MA. (2 hr CE) September 15, 2012

“Helping Patients Navigate the Ups and Downs of Multiple Sclerosis”. APhA. Los Angeles, CA. March 3, 2013. (2 hour CE) CO-Chaired event.

“Restless Legs Syndrome (RLS) Willis-Ekbom Disease (WED) Drug Action”. Webinar broadcasted to approximately 350 people. July 24, 2012. CO-Chaired event.

“MS Treatment in the 21st Century”. Boulder CO. (CE 2 hours)

“The Clinical Challenges Of Multiple Sclerosis” Managed Care and Specialty Pharmacist Perspectives”. July 20, 2012. This will become 4 Webinar’s and 2 interactive cases. CO-Chaired event.

“MS therapies 2012. CE 4 hours. 2012 Boston and HartFord.

“Multiple Sclerosis: Managing the Whole Patient.” APhA 2012. New Orleans, LA. March 12, 2012. (2 hour CE)

“Actionable Insights to the Evolving Management of MS: Important Considerations in Improving Outcomes”. “Clinically Isolated Syndrome: Why to Treat? Chair of the program. ASIM 2011. July 28, 2011 (1.5 hour CE) repeated 4 times.

“2011 Updates in Therapeutics. The Pharmacotherapy Preparatory Course. Epilepsy and Headache/Migraine.” ACCP 2011. Columbus, OH. April 9, 2011 (1 hour CE)

“Multiple Sclerosis and the Disease-Modifying Therapies.” APhA 2011. Seattle, WA. March 26, 2011. (2 hour CE)

“Medications Used to Treat RLS”. RLS Foundation. Regional Meeting Madison, WI. October 10, 2010.

“Brand vs. Generic, Is There a Difference for Antiepileptic Drugs”? ACCP Spring Practice and Research Forum. Charlotte, North Carolina. April 24, 2010. (CE)

“Medications Used to Treat Restless Legs Syndrome”. 2010 Regional Meeting, Banner Sun Health Research Institute. Sun City, Arizona. February 6th, 2010.

“Emerging Therapies in Epilepsy”. New Mexico Pharmacists Association. Albuquerque, NM. February 1, 2009. (1 hour)

“Therapeutic Landscape for Epilepsy in Long-Term Care.” 2008 Epilepsy Specialty Advisory Board. Denver, CO. October 10, 2008.

“2008 Epilepsy Specialty Advisory Board Series” Long Term Care. Las Colinas, Dallas, Texas. October 9-11, 2008.

“The Treatment of Restless Legs Syndrome.” RLS Foundation’s 2008 Regional Meeting in Chicago. “Reach out. Learn more. Step forward.” Chicago, IL. July 19th, 2008.

“What’s New In Neurology Medications: Neuroprotection: Parkinson’s disease, Multiple Sclerosis, Epilepsy, and Headache.” 33rd National

Primary care Nurse Practitioner Symposium. Keystone, CO. July 11, 2008 (CE)

“ Implications of Generic Substitution of Anti-Epileptic Drugs (AEDs) and Hospital Based Issues”. Managers of UCB Pharma. Chicago, IL. June 12, 2008.

“ The Many Roles of the Pharmacist”. Managers of UCB Pharma. Chicago, IL. June 12, 2008.

“Implications and Practices of Using the New AEDs Compared to the Older AEDS”. Phoenix, AZ. April 22, 2008.

“Managed Care Decision-Makers Consulting Meeting and AEDs”. Atlanta, Georgia. April 4 and 5, 2008.

“Disease Modifying Drugs in Multiple Sclerosis (MS)”. University of Colorado at Denver and the Health Sciences Center, Denver, CO. 2007. (CE)

Parkinson’s disease. Corporate Meeting Solutions. Phoenix, AZ. September, 2007. (CE)

“KEPPRA® program”. Dowden Health Media Education Group. Tucson, AZ. December 12, 2007.

“KEPPRA® program”. Dowden Health Media Education Group. Yuma, AZ. December 11, 2007.

“KEPPRA® program”. Dowden Health Media Education Group. Tucson, AZ. November 29, 2007.

“KEPPRA® program”. Dowden Health Media Education Group. Yuma, AZ. November 28, 2007.

I organized, grant funded this project and moderated the session. 3rd annual epilepsy and neurology update meeting. November 10, 2007. (5 CEU’s).

“KEPPRA® program”. Dowden Health Media Education Group. Phoenix, AZ. November 8, 2007.

“KEPPRA® program”. Dowden Health Media Education Group. Phoenix, AZ. November 1, 2007.

“Clinical Pearls in the Management of Parkinson’s Disease”. Phoenix, AZ. October 4, 2007.

“A Review of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AEDs”. MedAssets Supply Chain Systems. Teleconference. March 13, 2007. (CE)

Neuropharmacology of Antiepileptic Drugs. American Epilepsy Society. December 2006. (CE)

“The Use of the Vagus Nerve Stimulation in Seizure Disorders”. American College of Clinical Pharmacy. St. Louis, MO. October 2006. (CE)

“Using Pathophysiology to Optimize Therapeutic Approach”. American Managed Care Pharmacists (AMCP). Chicago, IL. October 4, 2006. (CE)

“Treatment Optimization in Practice: Multiple Sclerosis”. AMCP. Chicago, IL. October 4, 2006. (CE)

“Treatment Optimization in Other Chronic Diseases”. AMCP. Chicago, IL. October 4, 2006. (CE)

“Using the Newer AEDs Compared to the Older AEDs”. Fort Bliss Army Base, EL Paso, TX. July 28, 2006. (CE)

“Using the Newer AEDs Compared to the Older AEDs”. Fort Bliss Army Base, EL Paso, TX. July 27, 2006. (CE)

“Using the Newer Anti-Epileptic Drugs (AEDs) Compared to the Older AEDs”. Phoenix, AZ. May 24, 2006.

“Newer Anti-Epileptic Drugs (AEDs) Compared to the Older AEDs: Can We Continue to Justify Using Older AEDs?”. Portland, OR. March 28, 2006.

“Newer Anti-Epileptic Drugs (AEDs) Compared to the Older AEDs: Can We Continue to Justify Using Older AEDs?”. Seattle, WA. March 28, 2006.

“Practical Applications of Newer AEDs Compared to the Older AEDs: Can We Continue to Justify Using Older AEDs?”. Phoenix, AZ. December 19, 2005.

“Worsening MS Treatment”. Kansas City, MO. November 14, 2005.

“Contemporary Treatment of Epilepsy: Can We Continue to Justify Using the Older AEDs?”. Chicago, IL. October 29, 2005.

“New Antiepileptic Drugs (AEDs) in Clinical Practice”. FSHP. Jacksonville, Florida. June 16, 2005. (CE)

“When the Body Attacks: An Update on the Treatment of Immune Mediated Diseases”. National through CD ROM and Internet Presentation. January 2005. (CE)

“Pharmacology of Multiple Sclerosis and Disease Modifying Drugs”. 2nd Annual Neuro/Psych Symposium. Temecula, CA. October 16, 2004. (CE)

“Evidence Based Treatment of Epilepsy”. **Plenary Session**. AACP National Conference. Salt Lake City, UT. July 14, 2004. (CE)

“New Treatment Options in Multiple Sclerosis”. Kansas City, MO. March 17, 2004.

“New Onset Seizures in the Elderly”. AES. Boston, MA. December 5, 2003. (CE)

“Advances in Multiple Sclerosis”. Western University of Health Sciences College. Temecula, CA. November 23, 2003. (CE)

“The Use of IV Dexamethasone In Place of IV Methylprednisolone”. ACCP. Atlanta, GA. November 2003. (CE)

“The Use of Preventatives in the Treatment of Migraine”. Moderator and Speaker, ACCP. Atlanta, GA. November 2003. (CE)

“Neuronal Stabilization”. Moderator, ACCP. Atlanta, GA. November 2003.

“Pathophysiology and Immune Therapy in MS”. Illinois Pharmacy Society. Chicago, IL. October 2003.

“AED Serum Concentrations”. Moderator, ACCP . Palm Springs, CA. 2003.

“Medication adherence in chronic disorders”. Portland. OR. January 21, 2003. (CE)

“The Challenges of Patient Counseling and Adherence”. Seattle, WA. January 14, 2003. (CE)

“The Challenges of Patient Counseling and Adherence”. Las Vegas, NV. December 14, 2002. (CE)

“The Pathophysiology of Multiple Sclerosis (MS) and Immune Modulating Therapies”. ASHP midyear meeting. Atlanta, GA. December 11, 2002. (CE)

“The Challenges of Patient Counseling and Adherence”. Salt Lake City, UT. November 16, 2002. (CE)

“Medication adherence in Migraine, Depression and Herpes infections”. Phoenix, AZ. October 29, 2002.

“The Pathophysiology of Multiple Sclerosis (MS) and Immune Modulating Therapies”. Nurse Practitioner and Physician Assistant Continuing education program. Austin, TX. October 4-6, 2002.

“Ask the Experts – Epilepsy Foundation of America” Web-cast and live. Patients, caregivers, and health care practitioners. New Orleans, LA. September 14, 2002.

“Antiepileptic Drugs (AEDs) in Clinical Practice”. CEPA. San Diego, CA. May 2, 2002.

“Antiepileptic Drugs (AEDs) in Clinical Practice”. CEPA. New Port Beach, CA. April 24, 2002.

“Herbal Products, Interactions with Antiepileptic Drugs”. National Epilepsy Conference. New York City University, New York, NY. November 2001.

“First Line Treatment of Migraine: Analgesics or Triptans?”. ACCP focus session, Annual meeting, Tampa FL. October 22, 2001.

Parkinson’s disease (PD) The “Shaking Palsy” Syndrome. New Mexico Pharmaceutical Association. Albuquerque, NM. June 23, 2001

“The Many Faces of Epilepsy”. UCB Pharma Training session. Medical Science Associates and Sales Force in attendance. Phoenix, AZ. June 6, 2001.

“Antiepileptic Drug Choice Based on Mechanism of Action, Drug-Drug Interaction Profile and the Patient”. Park City, UT. November 11, 2000.

“Herbal Therapy and Epilepsy”. At the National Epilepsy Meeting in Atlanta. Atlanta, GA. August 11, 2000.

“Update on Antiepileptic Drugs”. Florida. July 15, 2000.

"Antiepileptic Drugs: A Review". Long Beach, CA., Grand Rounds. June 28, 2000.

"Update on Keppra® ". Northern California Medi-Cal Continuing Education Program. Stockton, CA. June 7, 2000.

“Practical Applications of Building a Rotating Specialty Residency.” ACCP meeting, Nashville, TN. 1996.

“Update on Depacon® - Clinical uses”. Las Vegas, NV. March 27, 2000.

“The Medical Management of Migraine”. The University of Oklahoma Department of Pharmacy, School of Pharmacy, and Medical Housestaff. Norman, OK. May 8, 2000.

D. International

“HMDDP Visiting Experts FY 2015 Ministry of Health Singapore” Start date November 16, 2015- November 25, 2015. Singapore (40 hours of CE). (CE)

“Novel Therapies for Brain Disease in Those Patients that are going Downhill Fast”. Winter Conference on Brain Research. Big Sky, Montana 1/29/2015. (2 hr CE).

“Management of AED Drug Interactions and Adverse Effects”. 2 hour workshop, repeated 3 times. Adriatic Summer Epilepsy School (ASES) International Epilepsy Teaching Course. Island of Sipan, Dubrovnik, Croatia. June 22-26th, 2011.

“AED Pharmacotherapy in Specific Groups”. 1 hour didactic lecture. Adriatic Summer Epilepsy School (ASES) International Epilepsy Teaching Course. Island of Sipan, Dubrovnik, Croatia. June 22-26th, 2011.

“Status Epilepticus”. 2 hour workshop, repeated 3 times. Adriatic Summer Epilepsy School (ASES) International Epilepsy Teaching Course. Island of Sipan, Dubrovnik, Croatia. June 22-26th, 2011.

“When to Educate Health Care Professionals”. National Institute of Neurological Disorders and Stroke Workshop on Sudden Unexpected or

Unexplained Death in Epilepsy (SUDEP). Moderator with Andres Kanner. November 12-14, 2008.

“When to Educate Health Care Professionals”. National Institute of Neurological Disorders and Stroke Workshop on Sudden Unexpected or Unexplained Death in Epilepsy (SUDEP). November 2009.

“Fact or Fiction” Brand AEDs vs Generic AEDs. **Plenary Parallel Session.** AES. Philadelphia, PA. November 30, 2007. (CE)

Invited guest to 2nd Eilat International Educational Course: Pharmacological Treatment of Epilepsy. Eilat, Israel. Small group instruction on pharmacokinetics. September 2-9, 2007. (CE)

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. August 7, 2007. (CE)

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. July 31, 2007. (CE)

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. July 24, 2007. (CE)

“Mastering Multiple Sclerosis: Challenges and Opportunities for Managed Care Pharmacists”. Webcast, University of Tennessee. July 17, 2007. (CE)

ACCP/ESCP CNS PRN Workshop in Paris, France. “Around The World-Implementing Guidelines into Clinical Practice”. Moderator. April 29, 2004.

“Adverse effects of topiramate use in children (poster)”. 23rd International Epilepsy Society. September 1999.

X. ADMINISTRATIVE ACTIVITY AND UNIVERSITY SERVICE

“HMDP Visiting Experts FY 2015 Ministry of Health Singapore” Start date November 16, 2015- November 25, 2015. Singapore (40 hours of CE). (CE)

“Restless Legs Syndrome (RLS) Willis-Ekbom Disease (WED) Drug Action”.

Webinar broadcasted to approximately 350 people (each date). July 24, 2012. October 25, 2012. CO-Chaired event.

ARPT committee 2012 - present

“The Clinical Challenges Of Multiple Sclerosis” Managed Care and Specialty Pharmacist Perspectives”. July 20, 2012. This will become 4 Webinar’s and 2 interactive cases. CO-Chaired event.

Chair of the Nontraditional PharmD Committee Now the Distance Degrees Program (DDP) 2011-2014

Chair of the search committee Director of Nontraditional Program – September 2008 – 2009

Participated in Morbidity and Mortality Neurology Conference reviewing a lorazepam and propylene glycol overdose during status epilepticus, October 1, 2008.

School of Pharmacy Accreditation Committee (ACPE) September 2008-present

School of Pharmacy Building Oversight Committee January 2008 - present

Search committee Director Clinical Affairs. January 2008 – August 2008

Experiential Committee, Subcommittee of the Curriculum Committee 2004 – present

Nicaragua Medical Mission Trip July 2006

Coordinator and grant writer The Annual Epilepsy Symposium at the Denver Country Club 2005

Coordinator and grant writer The Annual Epilepsy Symposium at the Denver Country Club 2004

Coordinator and grant writer The Annual Epilepsy Symposium at the Denver Country Club 2003

Postgraduate Institute of Medical Education (PIM); January 13, 1997 - present
University of Colorado School of Pharmacy

Colorado Multiple Institutional Review Board (COMIRB) Senior reviewer;
August 8, 1997 – present

Non-Traditional Pharm.D. Curriculum Committee June 19, 1997 – present

Course Director Pharm.D. Seminar 1996 – present

Course Director Integrated Organ Systems (IOS VIII) 2001 – present

COMIRB Education Day committee member 2003 - present

Course Director Advanced Drug Literature Evaluation 2004 – 2006

XI. PROFESSIONAL ACTIVITY AND PUBLIC SERVICE

A. Membership in Professional Organizations

National Restless Legs Syndrome Board of Directors. Member since 2006.

Chair, of the Board of Directors 2010-2015

Chair, Nominating committee. 2006-2009

Vice President, 2008-2011

Chair – Centers of Excellence. 2010 - present

Epilepsy Foundation of America (EFA). Member since 1996

Member and Content Reviewer, Professional Advisory Board, Content Advisory Committee (CAC) for Print material and Web material
September 5, 2008-present

Planning Committee, NINDS Sudden Unexpected/Unexplained Death in Epilepsy (SUDEP) Workshop to be held on November 12-14, 2008
Washington D.C.

Faculty, Leadership in Epilepsy, Advocacy, and Development (LEAD)
Providing Educational Support to the Epilepsy Community, December 2007

Member, Advocacy committee, Epilepsy Foundation of America (EFA)
Board of Directors (elected), May 2000 – present

Member, Epilepsy foundation of America (EFA), 2000 - present

Epilepsy Foundation of Colorado (EFC). Member since 1995

Past president, Epilepsy Foundation of Colorado (EFC) Board of Directors
(elected) 2002/2003

Past president, Epilepsy Foundation of Colorado (EFC) Board of Directors
(elected) 2001/2002

Past president, Epilepsy Foundation of Colorado (EFC) Board of Directors
(elected) 1998/1999

Member, Professional Advisory Board Epilepsy Foundation of Colorado,
September 30, 1997 – present

Founder, “Team Spike N Wave” (walkers, 1/2 M runners, century cyclists), fund raiser for The Epilepsy Foundation of Colorado 1997,

2002 – 2004

American College of Clinical Pharmacy (ACCP). Membership 1993
CO-Chair, Annual Meeting Committee, Appointed position, October 2014 - 2017

Member, FCCP Credentials Committee, Appointed position. October 2009 -2012.

Member, Fellowship Review Committee, Peer Review. Appointed position. October 2005-2008

Chair, Mini-sabbatical committee, ACCP CNS PRN. October 2003-2008
Central Nervous System (CNS) PRN

Chair, Programming Committee 1997 – 2000, 2002 - 2004

Chair, Policy and Nominations Committee 1997 - 2001

Chair, CNS PRN September 2002 – 2003

Immediate Past-Chair, CNS PRN 2003 – present

Member, Mini-sabbatical committee 2003

American Epilepsy Society (AES). Member since 1995.

Vice-Chair Medications working group, elected December 2014-2017

Member, Corporate Advisory Committee (CAC), Elected 2/7/2013 -

Member, Clinical Therapeutics Committee, Elected 12/2006 – 2014

Member, AES Access to Continuity of Supply Steering Committee 2007 – present

Member, AES SUDEP Committee 2007-present

Member, Clinical Neuropharmacy SIG 2006-present

Chair, AES Significant Interest Group 2003 - 2006

Member, Pharmacists In Epilepsy (PIE), 1994 - present

Continuing Education Committee, Colorado Pharmacist Association (CPA). December 2005-2008.

Member, Phi Lambda Sigma Leadership Society, Colorado chapter 1996 – present

Member, American Academy of Neurology (AAN), 1996 – present

Member, American Association of Colleges of Pharmacy (AACCP), 1996 – present

Member, The Colorado Pharmacists Association (CPhA), 1996 – present.
Now called CPA

Member, Rho Chi 1995- present

Member, Rocky Mountain Multiple Sclerosis (MS) Society, 1988 - present

Member, American Society of Health-System Pharmacists (ASHP), 1988 - present

Member, Colorado Society of Health-System Pharmacists (CSHP), 1988 present. Now called CPA

Member, Colorado Pharmacist Association (CPA), 2004- present

Member, Alpha Zeta Omega (Pharmaceutical Fraternity) 1986 – 1988

Member, Lambda Tau (Medical Technology Professional Organization)
1981 – 1986

B. Review Panels

“Restless Legs Syndrome (RLS) Willis-Ekbom Disease (WED) Drug Action”. Webinar broadcasted to approximately 350 people. July 24, 2012. CO-Chaired event.

“The Clinical Challenges Of Multiple Sclerosis” Managed Care and Specialty Pharmacist Perspectives”. July 20, 2012. This will become 4 Webinar’s and 2 interactive cases. CO-Chaired event.

2011 The Evolving Paradigms in Multiple Sclerosis: Focus on Early Identification and Treatment Initiation. CE Webinar x 3 and monograph.

2010 The Evolving Paradigms in Multiple Sclerosis: Focus on Early Identification and Treatment Initiation. CE Webinar x 4 and monograph.

2005-2007 The Wright Resource Healthcare Marketing Consultants
Multiple Sclerosis Clinician’s Guidebook

C. Journal Referee

Journal of the American Pharmacists Association
American Journal of Health-System Pharmacy
American Pharmaceutical Association
American Journal of Pharmaceutical Education
Pharmacotherapy
Annals of Pharmacotherapy
Journal of Pharmacy Technology
Journal of the American Psychiatric Nurses Association

D. Publications Reviewed as an Expert Reviewer

Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: A cross-sectional, cohort study. Pharmacotherapy. 4/2015.

Hong-Mei Meng. Early predictors and preventative treatment for post-stroke epilepsy: changes in glutamate, γ -aminobutyric acid, and calcium ion concentration in stroke patients
Seizure: European Journal of Epilepsy. 2014-307R1 10/01/2014.

George DeMaagd. Parkinson Disease and Its Management. Pharmacy and Therapeutics (P&T). 11/21/2013.

Implementing best practices for monitoring metabolic changes in outpatients taking atypical antipsychotic medications: Using Rosswurm and Larrabee's evidence-based practice model. File# JAPNA-2013-RP-046. Journal of the American Psychiatric Nurses Association. 6/2013.

Seymour, Nicole, Patel Tejal, Dixon, Heather. Gabapentin for Essential Tremor Followed by Worsening of Myasthenia Gravis. 12/11/12.

Coppyty Cruz-Cruz, Marina Altagracia-Martinez, Jaime Rios-Castaneda et al. Health related quality of life in patients post-stroke:dapsone vs. placebo. JR003. The Journal of Pharmacy Technology. 2/2012.

Desilets, Alicia, Koslowski, Danielle, Dunican, Kaelen The role of HMG-CoA reductase inhibitors in the prevention and treatment of Alzheimer's disease. File # JP-032. The Journal of Pharmacy Technology. 5/2010.

Jacquelyn L. Bainbridge. Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. Laura Borgelt, Karim Anton Calis, Mary Beth O'Connell, Judith A. Smith Section editor of the Neurologic Disorders chapters. Chapter 41. American Society of Health-System Pharmacists 2010.

Hale, Katherine S. "Milnacipran: A New Treatment for Fibromyalgia Syndrome". TheJournal of Pharmacy Technology. 12/09.

"Limited Potentiation of Blood Pressure in Response to Oral Tyramine by the Anti Parkinson Brain Selective Multifunctional Monoamine Oxidase AB Inhibitor, M30. Journal Neurotoxicity . 9/20/09.

"Sabril (Vigabatrin) – Informational Session. Written and Reviewed for EFA website. September, 2009.

"Medicines for Epilepsy." Expert Reviewer for Epilepsy Foundation of America. 10/15/08.

American Society of Health-System Pharmacists. Peripheral Neuropathy, chapter # 14. In: Jim Tisdale, Doug Miller eds. Drug-Induced Diseases: Prevention, Detection, and Management, 2nd ed. Bethesda, Maryland, 2009.

"Dosage form proportionality and food-effect of the final tablet

formulation of eslicarbazepine acetate in healthy volunteers”. *Drugs in R&D*. 6/2008.

“Factors potentiating the risk of mirtazaine-associated restless legs syndrome”. *Human Psychopharmacology*. 2/2008.

“Appropriate use of dopamine agonists and levodopa in Restless legs syndrome (RLS) patients in an ambulatory care setting”. *The Annals Pharmacotherapy*. 1/2008.

“Rash and liver dysfunction related to lamotrigine therapy: A case report and systematic review”. *The Journal of Pharmacy Technology*. October 2007.

“Is amantadine effective for promoting early arousal inpatients with traumatic brain injury?” *The Annals of Pharmacotherapy*. May 2007.

“Carbamazepine Dose-Concentration Relationships in Elderly Nursing Home Residents.” *Epilepsy Research*. May 2007.

PSAP-VI Neurology/Psychiatry. Ellen Whipple Guthrie. Multiple Sclerosis. In: Dunsworth T, Richardson M, Cheng J, et al, eds. *Pharmacotherapy Self-Assessment Program*, 6th ed. Neurology. Lenexa, KS: American College of Clinical Pharmacy, 2007:1-17.

Management of Pain: Balancing Efficacy with Safety and Tolerability. SynerMed Communications. March 6, 2007.

“Impact of a Pharmacist Intervention on Migraineur Physician-Consulting Behavior.” *Manuscript Central*. March 5, 2007.

“Impact of a Pharmacist Intervention on Migraineur Physician-Consulting Behavior.” *Journal of the American Pharmacists Association*. February 2007.

The use of Tysabri® in multiple sclerosis patients. *Drug Topics*. July 2006.

“Should Gabapentin Be Dose Adjusted: What are the Clinical Consequences”? *The Journal of Pharmacy Technology*. 6/2006.

“A Pharmacotherapy Clinic in a Neurology Practice”. *The Journal of Pharmacy Technology*. 5/2006.

“Intractable Epistaxis Associated with Topiramate Administration Category – Case Report”. *The Annals of Pharmacotherapy*. 3/2006.

“Discrepancies Between Student and Preceptor Perception in Advanced Pharmacy Practice Experiences”. American Journal of Pharmaceutical Education. 6/2004.

“Thrombosis Secondary to Medroxyprogesterone in Patient at Risk for Thromboembolism”. The Journal of Pharmacy Technology. 12/20/2004.

“Comparison of Pharmacokinetics and Safety of Divalproex Sodium Extended-Release Tablets Following Morning Versus Evening Dosing. American Journal of Health-System Pharmacy. 2/2004.

“Missing a Daily Dose of Divalproex Sodium Extended-Release Tablets: What Do You Tell the Patient to Do?. American Journal of Health-System Pharmacy. 2/2004.

“MS Therapies”. Reviewed for the Journal of Pharmacy Technology. 2/2004.

“Alzheimer’s Disease”. Reviewed for the Journal of Pharmacy Technology. 2/2004.

“Epilepsy”. Reviewed for the Journal of Pharmacy Technology. 2/2004.

“Why Do Patients Discontinue Multiple Sclerosis Therapies? Journal of the American Pharmaceutical Association. 1/2004.

“Monograph review of Agents for Multiple Sclerosis”. University HealthSystem Consortium. 1/2004.

“Case-Control Comparing Droperidol Plus Diphenhydramine to Conventional Treatment in Hyperemesis Gravidarum”. Reviewed for the Journal of Pharmacy Technology. 2/2003.

“Galantamine: A new agent for the treatment of Alzheimer’s disease”. Reviewed for the American Society of Health-System Pharmacists (ASHP). 8/29/02.

Clinical considerations in the management of MS with interferons. CE Course monograph sponsored by Ithaca for center Postgraduate medical Education. (CD program, audiotape and live). 2/2002.

Severe Thrombocytopenia and Antiepileptic Hypersensitivity Syndrome. Epilepsia. 2/2002.

Appropriateness of antiepileptic concentration monitoring in hospitalized

children. The Journal of Pediatric Pharmacology and Therapeutics (JPPT) 7/2001.

Herbal Medicines and Epilepsy: The Potential for Adverse Effects. Marcello Spinella. Epilepsy and Behavior. July 2001.

“Antiepileptic Drugs”. American Journal of Pharmaceutical Education. 1/17/2001.

Providing Pharmaceutical Care to the Multiple Sclerosis Patient (00-111). Journal of the American Pharmaceutical Association. 1/4/2001.

“A Review of Valproic Acid and Carnitine Deficiency” (10206-A). The Journal of Pharmacy Technology. 07/10/00.

“The Role of Carnitine Supplementation During Valproic Acid Therapy” (9294 A). The Annals of Pharmacotherapy 07/29/99.

Expert opinion for a patient at University of Colorado Hospital. This case was reviewed and written up and forwarded to Professional Risk Management at The University of Colorado Hospital. 04/12/99.

“Complicated Urinary Tract Infections in the Elderly”. Postgraduate Institute for Medicine. 04/01/99.

“Case Studies in Multiple Sclerosis”. Postgraduate Institute For Medicine. 04/01/99.

“Tolcapone in Parkinson’s Disease” (5717). American Society of Health-System Pharmacists. 02/25/99.

“Absorption of Rectally Administered Phenytoin” (F8335). The Annals of Pharmacotherapy. 12/04/98.

E. Public Service

International RLS Study Group (IRLSSG) and European RLS study Group (EU-RLSSG) 2015 RLS/WED Science Summit Monterey, CA October 22- October 25, 2015.

Community Recreation Center of Apex, 6842 Wadsworth Blvd, Arvada CO. Student Elderly Brown Bag. March 14, 2013.

Boulder Community Center lecture on RLS/WED February 2013.

Epilepsy Patient Advocate Presentation. Denver Heath Medical Center

and University of Colorado. July 31st, 2012.

RLS patient webinar. July 24th, 2012

Cedar shadow program APhA 2011, 2012, 2013, 2014

Student lunch program – Phi Delta Chi 2010, 2011, 2012, 2013, 2014

Student shadow program at Arapahoe House APhA 2010, 2011, 2012, 2013, 2014 several times.

CSSHP Faculty Dinner. Several in 2010, 2011, 2012, 2013, 2014

NeuroTalk 2010: Invited guest to Singapore June 25-28, 2010. Track 4-12 Major Neural Disease: Parkinson's Disease Drug Discovery. This will be at the 1st Annual World Congress. I have not accepted this invitation.

Updated the International Database on Antiepileptic Drugs (AEDs) for the Epilepsy Foundation of America (EFA), December 2009.

Updated the Antiepileptic Drug (AED) serum concentration brochure for Children's Hospital Neurology Department, November 2009.

CSSHP Faculty Dinner. Several in 2009.

CSSHP Faculty Dinner. October 13, 2008.

Citizen Petition for Shire Pharmaceuticals Group. Sept 2008.

Arapahoe House Brown Bag as advisor with students October 3, 2008

Pharmacology Treatment of Epilepsy. Invited by The Hebrew University of Jerusalem, Israel, ILAE Commission on European Affairs (CEA), European Epilepsy Academy (EUREPA) and the Epilepsy Therapy Development Project, held in Eilat, Israel. September 2-9, 2007

Medical Mission Trip to Nicaragua, July 5-16, 2005

Medication Assistance Program (MAP) coordinator in Neurology 2000 – 2005

Epilepsy camp for children who have epilepsy August, 8/12/2001 – 8/16/2001, 2002, 2003, 2004

Colorado 9 Health Fair 2001 (pharmacy brown bag) 2001

Ask a professional about multiple sclerosis (channel 4) 3/18/99

CPR teaching to Health Care Professionals, 1991 – present

Colorado 9 Health Fair (general medical screening), 1999-2000

F. Editorial Board

ASIM Spectrums. Co-Chair. Web-based presentations/ publications/ live presentations. 2014.

ASIM Co-Chair CE live and Web-based presentations/publications. 2013 and 2014.

ASIM Co-Chair CE program on Multiple Sclerosis and Web-based Case Series 2012 and 2013.

Lacosamide moderator and Advisory Board. Atlanta, GA May 21-22, 2010.

2008 Epilepsy Clinical Advisory Board. Chicago, IL. October 23-24, 2008.

Treating the Whole Patient Advisory Board. New Orleans, LA. Health Learning Systems. October 20-22, 2008.

“When to Educate Health Care Professionals”. National Institute of Neurological Disorders and Stroke Workshop on Sudden Unexpected or Unexplained Death in Epilepsy (SUDEP). Moderator with Andres Kanner. November 12-14, 2008.

Lacosamide moderator and Advisory Board. Dallas, TX. October 10-11, 2008.

Keppra XR Speaker Training Meeting 2008. San Diego, CA. September 26-27, 2008.

Continuity of Supply Task Force. Appointed 2007 – present.

Clinical Therapeutics Committee AES. Elected 12/2006 – 2009.

Shire US Inc. Carbatrol® National Advisory Board 2007-present.

NeuroNews. (CE) volume 1, Issue 3. Spring 2007.

A Review of Using the Newer Antiepileptic Drugs (AEDs) Compared to the Older AEDs. CE Teleconference. March 2007.

Treatment Optimization Strategies for Multiple Sclerosis: Working to Improve Outcomes While Managing Costs. (CE) February 2007.

Novartis Preceptorship coordinator – University of Colorado Health Sciences Center. March 16 and 17, 2005.

Postgraduate Institute For Medicine (PIM) – Editorial Board, Board of Directors – 1995 – present.

MICROMEDEX® Editorial board 1997 – present.

Parke-Davis Speakers Bureau - Minnesota, May 5, 1997 to June 1, 1997. To be continued.

Clinical Pharmacist Advisory Meeting and Board November 8, 1997 to November 11, 1997. To be continued.

Advisory Board – Abbott Pharmaceuticals – 1998 – present

Stroke Advisory Board – Bristol Myers Squibb November 1998. To be continued.

UCB Pharma – epilepsy advisory board 2000 – present

Novartis – epilepsy advisory board 2000 – present

Pfizer – dementia advisory board 2000 – present

Elan - advisory board 2000-present

Glaxo Wellcome - advisory board 2000-present

COPD Advisory Board Postgraduate Institute for Medicine
June 28-29, 2001 – present.

Serono, Inc. neurosciences consultant beginning May 2002 – present.

King's Pharmaceutical. February 2004 – present.

Eisai Pharmaceutical Roundtable. April 2004 – present.

G. Grant Review

Epilepsy Foundation of America (EFA). Reviewing two grant proposals for Morbidity and Mortality. May 13, 2015.

Epilepsy Foundation of America (EFA) and the Epilepsy Therapy Program. Reviewed two grant proposals. I was primary on one application and secondary on the other one. June 12, 2014.

Epilepsy Foundation of America (EFA). Reviewed two grant proposals. Primary on Two. January, 2014.

Epilepsy Foundation of America (EFA). Reviewed two grant proposals. I was the primary grant reviewer on two proposals. June 20, 2013.

Epilepsy Foundation of America (EFA). Reviewed two grant proposals. One grant I was the primary reviewer and the second grant I was the secondary reviewer. June 1, 2012.

Epilepsy Foundation of America (EFA). Reviewed three grant proposals. One grant I was the primary reviewer and the other two grants I was the secondary reviewer. June 1, 2011.

ACCP Frontier Fund review of a marker used for substance abuse. 2007

H. Professional Growth

ACCP meeting Anaheim 10/18-10/21/2009

ACCP meetings 2010, 2011, 2012, 2013, 2014, 2015

Leadership conferences quarterly 2010- present

Leadership mentor: Robert Waterman 2010-present

XII. ADVISING ACTIVITY

1996 – Present. Pharm.D. students and Bachelor of Science students

Neurology Specialty Resident (Preceptor supported)

1 year Scott Pollock 09/98-10/99

Neurology Clinical Research Fellow (Preceptor supported)

1 year Scott Pollock 09/99-10/00

Neurology Specialty Resident (Preceptor supported and University of Colorado Hospital supported)

1 year Sunita Dergalust 09/99-10/00

Neurology Specialty Resident (Preceptor supported and University of Colorado Hospital supported)

1 year Janina Janes 06/00-07/01

Neurology Fellow (Preceptor supported)

2 year Sarah Johnson 06/07-06/09

Research Assistants

1 year Nancy Regale 09/98 – 03/99

2 years Sharon Edwards 04/01- 03/03

2 years Vanessa Winzenburg 4/01-3/03

Work Study Students

1 year Brooke Glasmann 08/2008

2 years Caitlin Butler 05/2013

Neurology Fellow (Preceptor supported)

2 year Michael Egeberg 7/09 – 7/11

Independent Study Student (2 semester credits)

6 months Holly Cooper 7/10-01/11

Neurology Fellow (Preceptor supported)

1 year Jeffrey Clark 7/6/11-7/1/12

Neurology Fellow (Preceptor supported)

1 year Caleb Oh 7/23/12-7/20/13

Neurology Fellow (Preceptor supported)

2 year Pei Shieen Wong 09/17/2013-09/2015

Honors Student Projects

Steven Merrill (P3)	6/2012-6/2014
Stephanie Dunlap (P3)	6/2012-6/2014
Rachel Riddell (P3)	6/2012-6/2014
Caitlin Butler (P2)	6/2012-6/2015
Kathleen Athern (P2)	3/1014-6/2016
Jillian Bishop (P2)	8/2014-6/2016

Neurology Fellow (Preceptor supported)

2 year Felecia Hart 8/2015-7/2018

XIII. SPECIAL ASSIGNMENTS

Chair of the search committee for the director of the Non-Traditional Pharm.D. Program September 2008 closed

XIV. OTHER CREATIVE ACTIVITIES

None

XV. GRANTS AND RESEARCH

Under Preparation:

CDPHE Medical Marijuana grants:

Efficacy and Safety of Medical Marijuana in Adults with Tremor Predominate Parkinson Disease.

Sponsor: CDPHE

Principal Investigator: Maureen Leehey, M.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Efficacy and Safety of Medical Marijuana in Adults with Intractable Epilepsy

Sponsor: CDPHE Medical Marijuana grant

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

\$ 1,499,767.98 Not funded

Efficacy and Safety of Medical Marijuana in Adults with Epilepsy

Sponsor: CDPHE Medical Marijuana grant

Principal Investigator: Archana Shrestha MD

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

\$ 500,000.00 Not funded

Longitudinal Pharmacokinetic Profiling of Patients Self-Seeking a High Concentration Cannabidiol Marijuana (Charlotte's Web) From Naïve to Saturation Kinetics, in a Variety of Disease States.

Sponsor: CDPHE Medical Marijuana grant

Principal Investigator: Edward Maa MD

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

\$ 500,000.00 Not funded

Skaggs outcomes research proposal "disease modifying therapies for multiple sclerosis.

4/2013 – not funded

Proconvulsant and Anticonvulsant Effects of SSRI Antidepressants.

Sponsor: EFA

Principal Investigator: Anne Libby, PhD

Co-Investigator: **Jacquelyn Bainbridge, Pharm.D.**

Start date: 7/1/12-6/30/12

\$ 60,000.00

Mitochondrial DNA in Parkinson's disease Patients. Identifying Who Should Receive Which Neuroprotectant.

Sponsor: NINDS, part of the NET-PD effort

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Funding in progress: Expected start date:06/2013

Budget not yet finalized

Active Grants:

A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis of Cannabis versus Oxycodone.

Sponsored by CDPHE

Principal Investigator: Emily Lindley PhD

Co-Investigator: Jacquelyn Bainbridge, PharmD

Coordinator: Felecia Hart, PharmD

Start Date: January 1, 2016 – December 31, 2018

\$ 75,000 per year

Clinical Research Fellowship in Neurology. Funding to general fellowship project.

Sponsored by Supernus Pharmaceutical Inc FY 2015

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**, Felecia Hart, Pharm.D.

Start Date: October 1, 2015 – September 30, 2016
\$ 15,000.00 per year

Epilepsy and its comorbidities: building evidence from clinical outcomes and plasma biomarkers

Sponsored by SSPPS FY2015

Principal Investigators: **Jacquelyn L. Bainbridge, Pharm.D.**, Manish Patel, PhD, Anne Libby PhD, Molly Huntsman, PhD, Pei Shieen Wong, Pharm.D.

Start Date: December 2014 – December 2016

\$ 60,000.00 per year (20% FTE)

Zone study.

Sponsored by NINDS

Principle Investigator: Maureen Leehey, M.D

Co- Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

\$ 10,000 per year. (I am 5% FTE) Start date: 4/2011 – 10/2014

PAIR Leadership Award.

Sponsored by an award through The Patient Centered Outcomes Research Institute (PCOR).

Principal Investigator: Benzi Kluger, M.D.

Co-Investigator: Jacquelyn Bainbridge, Pharm.D.

Funding for meals. Start date: 5/2014-5/2015.

A Multicenter, Double-Blind, Parallel Group, Placebo Controlled Study Of Creatine In Subjects With Treated Parkinson's Disease (PD) LS-1.

Sponsored by NINDS

Principle Investigator: Maureen Leehey, M.D

Co- Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

\$ 30,000 per year. (I am 5% FTE) Start date: 2/2007 – 10/2014

Year 2011 – 4.34 % 6,060.00 and Pei Shieen Wong 47%

Lacosamide in the Elderly.

Sponsor: UCB pharma, Inc.

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Funding in Progress: August 1, 2013 – September 1, 2015

15,000.00

Intractable Seizure Patients Vs. Non-Intractable: Gender Differences In Elderly Patients.

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: Data base review after # 428 VA cooperative study, no additional funding

Percent effort 1% (Secondary analysis)

Pharmacoadherence A Function Of Seizure Control?

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: Data base review after # 428 VA cooperative study, no additional funding

Percent effort 1% (Secondary analysis)

Intractability In Elderly Onset Epilepsy Due To Pharmacoadherence.

Principal Investigator: Edward H. Maa, M.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: Data base review after # 428 VA cooperative study, no additional funding

Percent effort 1% (Secondary analysis)

Seizure-Free Patients Completed/ Non-Completed Patients: Of The VA #428 Study And Risk Factors.

Principal Investigator: Edward H. Maa, M.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: Data base review after # 428 VA cooperative study, no additional funding

Percent effort 1% (Secondary analysis)

Epilepsy Seizure Patients, Elderly, Time To Diagnosis.

Principal Investigator: Edward H. Maa, M.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: Data base review after # 428 VA cooperative study, no additional funding

Percent effort 1% (Secondary analysis)

Past Grants:

Outcomes research grant funded by the Epilepsy Foundation of America 2010.

Principal Investigator: Anne Libby

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Funding: 3,122.00

Percent effort: 2%

Efficacy of Bumetanide Add-on Therapy in Pharmacologically Intractable Adult Temporal Lobe Epilepsy Patients.

Principal Investigator: Edward H. Maa, M.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: \$ 6,000.00 for data collection/technical support for Denver Health

Start date: October 2007 - present
Percent effort 1% (Consultation and Analysis)

Safety And Efficacy Of Intravenous Levetiracetam Used For Seizure Prophylaxis In Subarachnoid Hemorrhage.

Principal Investigator: Edward H. Maa, M.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: Investigator initiated not funded Start date: 1/2006-present

Percent effort 1% (Consultation and Analysis)

“Evaluating Patterns of Monitoring for Multiple Sclerosis; Safety of Drug Therapy and Co-morbidities and Associated”

Sponsored by NOVARTIS - Medstat Database from 2000-2007 MS.

Principle Investigator: Kavita Nair, Ph.D.

Co-Investigators: **Jacquelyn L. Bainbridge, Pharm.D.**, John Corboy, M.D, Joseph Saseen, Pharm.D., Richard Allen, Pamela Wolfe.

Grant: \$ 103,481 Start date: 10/01/08-09/30/09 (I am 5% or 1.25 FTE - 2,556.00)

A Double-Blind, Randomized Study Comparing Levetiracetam And Carbamazepine In Elderly Patients With Partial Onset Seizures.

Sponsored By Miami International Epilepsy Center, Miami VA And Denver VA

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Co-Investigator: Mark C. Spitz, M.D.

\$~ 10,000 per year. Start date: 01/06-02/09.

“New Insights on Current and Future Therapies for Multiple Sclerosis”

Sponsored by ProCE, Inc., ECTRIMS MS Meeting 2008 – Developed slide deck and program

Principal Investigator: Sarah Johnson, Pharm.D.

Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Grant: \$ 2,500 Start date: 10/23/08-11/06/08

NINDS Sudden Unexpected/Unexplained Death in Epilepsy (SUDEP) Workshop. November 12-14, 2008.

Sponsor: NINDS

Principal Investigator: Elson So, M.D.

Co-Investigator: **Jacquelyn Bainbridge, Pharm.D.**

(Funding is for the conference only)

A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of Ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures.

Sponsor: Marinus Pharmaceuticals, Inc.
Protocol Number: 1042-0600
Study Phase: IIb
Study Drug: Ganaxolone (CCD 1041:3alpha-hydroxy-3β-methyl-5alpha-pregnan-20-one)
Principal Investigator: Mark C. Spitz, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge**, Pharm.D.
Start date: 02/2008-02/2009

ACTS part of NET-PD
Sponsor: NINDS
Principal Investigator: Maureen Leehey, M.D.
Co-Investigator: **Jacquelyn Bainbridge, Pharm.D.**
Grant: \$ 20,000 Start date: 03/01/09
Percent Effort: 3% Project cancelled

Protocol U278g. A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study To Evaluate The Safety And Efficacy Of Rituximab In Adults With Primary Progressive Multiple Sclerosis. COMIRB # 04-0935
Sponsored by Genetech.
Principal Investigator: John Corboy, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
Grant funding to help support Fellow \$20,000 Start date 7/2008 – 7/2009
(Technical support/ patient exams)

COMBI Rx Phase III – A Multi-Center, Double-Blind, Randomized Study Comparing The Combination Use Of Interferon Beta-1a And Glatiramer Acetate To Either Agent Alone In Patients With Relapsing-Remitting Multiple Sclerosis. COMIRB # 04-0895
Funded by the NIH/NINDS
Principal Investigator: John Corboy, M.D.
Sub-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 500.00 per year for 2 years Grant support for Fellow. (Technical support/ patient exams)
Start date 7/2008 – 7/2009

A Double-Blind, Placebo-Controlled, Dose-Ranging Study To Establish Efficacy, Safety And Tolerability Of RWJ-333369 As Adjunctive Therapy In Subjects With Refractory Partial Seizures.
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ ~ 20,000 per year. Start date: Cancelled

NIH Neuroprotection Trial In Parkinson's Disease. A Randomized Clinical Trial of Coenzyme Q10 and GPI-1485 in Early Parkinson's Disease.

Principal Investigator: Maureen Leehey, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ ~ 45,000 per year. Start date: 3/04 – 02/07

NIH Neuroprotection Trial In Parkinson's Disease. A Randomized Clinical Trial of Minocycline and Creatine.
Principal Investigator: Maureen Leehey, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ ~ 45,000 per year. Start date: 4/02 – 02/04

Disease Modifying And Treatment Updates In Parkinson's Disease And Multiple Sclerosis.
Presenter: **Jacquelyn L. Bainbridge, Pharm.D.**
Educational grant
Grant from Teva: \$1500 per session. Start date 1/2007 – 6-2008

Unpredictability Of Gastric Absorption Of Oral Levetiracetam In Critical Care Patients. Principal Investigator: Edward H. Maa, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
Grant: UCB Pharma \$ 10,000 for data collection Start date: 1/2006-11/2007
Percent effort 1% (Data Collection)

2007 Parkinson's Disease Collaborative Care Roundtable.
Presenter: **Jacquelyn L. Bainbridge, Pharm.D.**
Educational grant
TEVA awards \$1000 for participation. November 15-16, 2007.

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel-Group Phase III Study To Determine The Efficacy And Safety Of Retigabine (1200 Mg Per Day) Used As Adjunctive Therapy In Refractory Epilepsy Patients With Partial-Onset Seizures, 301 And 303 (Open-Label).
Principal Investigator: Mark Spitz, M.D.
Co-investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
Valeant Pharmaceuticals: \$ 2000.00 Start date 1/2006-7/2008.

Third Annual Epilepsy Treatment Symposium. Denver Health Medical Center.
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
Educational grant
\$ 30,000 per year. Sponsored by Pfizer and Ortho-McNeil Pharmaceuticals. Started: November 9-10, 2007

Second Annual Epilepsy Treatment Symposium. Denver Country Club.
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 15,000 per year. Sponsored by Pfizer and Ortho-McNeil

Pharmaceuticals. 11/2006

First Annual Epilepsy Treatment Symposium. Denver Country Club.
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 15,000 per year. Sponsored by Pfizer and Ortho-McNeil
Pharmaceuticals. 08/2005

A Multi-Center, Randomized, Blinded, Parallel-Group Study Of Avonex®
Compared With Avonex® In Combination With Oral Methotrexate,
Intravenous Methylprednisolone, Or Both In Subjects With Relapsing-
Remitting Multiple Sclerosis Who Have Breakthrough Disease (ACT).
COMIRB # 04-0027 (Grant # G630). Sponsored by Biogen Idec.
Principal Investigator: John Corboy, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 5000 per year. Start date: 02/05-04/06

VA Cooperative Study Of New Onset Seizures In The Elderly # 428.
COMIRB # 97-190.
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ ~ 60,000 per year. Start date: 9/97 – 04/03

VA Cooperative Study Of New Onset Seizures In The Elderly # 428.
Principle Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
To hire a research assistant. Start date 09/01/00-04/01/03
\$ 30,000 per year.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group,
Multicenter Study To Determine The Safety And Efficacy Of
Natalizumab®, When Added To Avonex® (Interferon Beta-1a), In
Subjects With Relapsing-Remitting Multiple Sclerosis (SENTINEL) C-
1802
Sponsored by Biogen/Elan pharmaceuticals
Principle Investigator: John Corboy, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 5,000.00 per year or 5% effort. Start date 9/2002-9/2003

“An Open-Label Study To Determine The Effect Of Topiramate On
Seizures In Elderly Patients With Partial Onset Seizures” (Protocol #
CAPSS-106).
Sponsor by Ortho-McNeil.
Principle Investigator: Mark C. Spitz, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 5,000.00 per year or 5% effort. Start date 11/2002-11/2004

Long-Term Comparison Of Adjunctive Vagus Nerve Stimulation To
Adjunctive New AED Treatment For Patients With Refractory Partial

Seizures. Cyberonics. Start 12/02 – Cancelled.
Principle Investigator: Mark C. Spitz, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Impact Extension Trial – Secondary Progressive Multiple Sclerosis C98-838. Start date 6/00 – 1/02
Principle Investigator: John Corboy, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 2,000 per year

Residency – Neurology/Pharmacy Project
Sponsored by Novartis Pharmaceutical
\$ 5,000 per year on an annual basis
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
Start date 2/02 –awarded 2002, 2003

Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study To Evaluate Safety And Efficacy Of Oral Fampridine-Sr (10 Mg B.I.D.) In Subjects With Multiple Sclerosis (Ms-F203). COMIRB # 04-0959
Sponsored by Acordia. Cancelled.

"An Open Label, Dose Titration Trial To Determine The Tolerability And Efficacy Of Oral SMA 927 As Adjunctive Therapy In Patients With Partial Seizures With Or Without Secondary Generalization. Start date 1/02 – 06/02.
Principle Investigator: Mark C. Spitz, M.D.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 10,000 used to help fund research department

Aricept® In Multiple Sclerosis
Principle Investigator: John Corboy, M.D. Start date: 01/01/02 – 08/02.
Co-Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 2,000

Tolerability Of Depacon®, High Dose And/Or Rapid Infusion
Principle Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$1,500 Abbott Pharmaceuticals Start date: 1/00 – 6/00.

“Clinical Research Fellow In Neurology/Pharmacy”.
1 year funding
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**
\$ 40,000 Pfizer Start date: 8/1/00

“Residency – Neurology/Pharmacy”
1 year funding
Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

\$ 37,000 Pfizer Start date: 8/1/99

“Lamotrigine Monotherapy”

Principle Investigator: Jose Cavazos, MD, PhD.

Study Coordinator & Co-investigator:

Jacquelyn L. Bainbridge, Pharm.D.

\$ 40,000 GlaxoWellcome Start date: 7/1/98 – 4/99 Cancelled

Herbal Usage In An Epilepsy Clinic – Multicenter

Principal Investigator, Denver **Jacquelyn L. Bainbridge, Pharm.D.**

Co-investigator: Barry Gidal, Pharm.D.

Start date: 08/12/98 – 06/99.

Data analysis

IMPACT Study – Secondary Progressive Multiple Sclerosis

Principle Investigator: John Corboy, M.D.

Examining technician & Co-investigator:

Jacquelyn L. Bainbridge, Pharm.D.

“Residency – Neurology/Pharmacy”

1 year funding

Jacquelyn L. Bainbridge, Pharm.D.

\$ 35,000 Pfizer Start date: 8/1/98

“Epilepsy Professional Journal Club”

Monthly Meetings.

Principal Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**,

Dianne L. Shantz, RN, MSN

\$ 1000. 4/28/97 – 12/99.

“Dosing Partners.” 1997.

Principle Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Co-investigator: Dianne L. Shantz, RN, MSN

\$ 100 per patient. Cancelled.

“Dosing Patterns And Quality Of Life.”

Principle Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Co-investigator: Dianne L. Shantz, RN, MSN

\$ 1,500 Novartis Pharmaceuticals. Target start date: 9/97.

“Fosphenytoin IV Vs. IM.” 1996 - 1997.

Principle Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Co-investigators: Mark C. Spitz M.D., John Towbin M.D.

Study Coordinator: Dianne L. Shantz, RN, MSN

\$ 40,000 Parke-Davis.

“Quality Of Life In Epilepsy.” 1996.

Principle Investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

Co-investigators: Douglas N. Fish, Pharm.D.

Mark C. Spitz, M.D., Dianne L. Shantz, RN, MSN, John Towbin, M.D.

“Chest Trial: Ha-1a.” 1992.

Principle Investigator: Charles Lawton

Co-investigator: **Jacquelyn L. Bainbridge, Pharm.D.**

“Comparative Study Of H2 Blockers In Total Parenteral Nutrition (TPN): Efficacy And Left Ventricular Function.” 1992.

“Serum Drug Assay Times In Relationship To Drug Administration Times In The ICU.” 1992.

“Neuromuscular Blocker Used In Conjunction With Sedative And Analgesic Agents.” 1992.

“Albumin Due - Hospital Guidelines.” 1991.

“Pharmacy Profile Reconciliation With The Nursing Medication Administration Record, Recording The Severities Of Discrepancies.” 1990 - 1993.

“Vitamin K Administration In Conjunction With TPN.” 1990.

Training and Personal Grants:

Grant funding ascertained by Principal Investigator Jacquelyn L. Bainbridge, Pharm.D.. Funding derived from active and past grants to support either residency or fellowship training. In some instances the funding was provided to directly support the training of specific individuals; these instances are noted below.

Neurology Specialty Resident (Preceptor supported)

1 year Scott Pollock 09/98-10/99 \$ **35,000 (specific funding)**

Neurology Clinical Research Fellow (Preceptor supported)

1 year Scott Pollock 09/99-10/00 \$ **37,000 (specific funding)**

Neurology Specialty Resident (Preceptor supported and University of Colorado Hospital supported)

1 year Sunita Dergalust 09/99-10/00 \$ **30,000 (specific**

funding)

Neurology Specialty Resident (Preceptor supported and University of Colorado Hospital supported)

1 year Janina Janes 06/00-07/01 \$ 32,000 (specific funding)

Neurology Fellow (Preceptor supported)

2 year Sarah Johnson 06/07-06/09 \$ 35,000 year 1/ \$ 42,000
year 2 (specific funding)

Research Assistants (Veterans Administration)

1 year Nancy Regale 09/98 – 03/99 \$ 15,000

2 years Sharon Edwards 04/01- 03/03 \$ 30,000

2 years Vanessa Winzenburg 4/01-3/03 \$ 62,901

Work Study Students

1 year Brooke Glasmann 08/2008

Neurology Fellow (Preceptor supported)

2 year Michael Egeberg 7/09 – 7/11 \$ 37,000/yr.

Independent Study

6 months Holly Cooper 7/10-01/11

Neurology Fellow (Preceptor supported)

1 year Caleb Oh 7/23/12-7/20/13

2 year Pei Shieen Wong 9/17/2013-9/2015

XVI. PUBLICATIONS

A. Refereed Journals (Peer Reviewed)/ In progress

White paper Augmentation Munich Germany December 11, 2014.

**Sex Differences in Clinical Features of Early, Treated Parkinson Disease
NINDS October , 2, 2014**

Clinical Practice Guidelines for the Diagnosis and Treatment of Restless Legs Syndrome/Willis-Ekbom Disease During Pregnancy and Lactation. Daniel L. Picchiette, Jennifer G. Hensley, **Jacquelyn L. Bainbridge**, Kathryn A. Lee, Mauro Manconi, James A. McGregor, Robert M. Silver, Claudia Trenkwalder, and Arthur S. Wlaters. On behalf of the International Restless Legs Syndrome Study Groupe (IRLSSG). 2014.

Dopamergic Treatment Choice. The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease (NET-PD) Investigators. 2014.

Lacosamide in the aged population. Original research. 2014.

Oxcarbazepine withdrawal article. May 1, 2014.

Neuropathic pain in CV patients, which AED do we use??

Refereed Journals (Peer Reviewed)/ Currently Under Review

A Randomized Trial of Creatine Monohydrate for Parkinson disease progression. The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease (NET-PD) Investigators. 2014.

The NINDS NET-PD Investigators. Design Innovations and baseline findings in a long-term Parkinson's Trial. July 2013.

Tracy Glauser, **Jacquelyn Bainbridge**, Thomas Bleck, W.E. Dodson, Lisa Garrity, Andy Jagoda, Dan Lowenstein, Jack Pellock, Jim Riviello, Ed Sloan, David Treiman, Shlomo Shinnar. Treatment of Convulsive Status Epilepticus in Adults and Children: Treatment Guideline. 2013

LEAD White Paper on AED Substitution. Core Elements of Epilepsy Diagnosis and Management: Expert Consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) Faculty. Tracy Glauser, Raman Sankar (Co-chairs), (Faculty) **Jacquelyn L. Bainbridge**, Martina Bebin, Selim R. Benbadis, et al. There are 26 Lead Faculty in all. Under Review - submitted to CNS spectrums to be published in 2009. All authors contribute equally to the concept, collection of data, discussing the results and writing the manuscript.

Connie Valdez, **Jacquelyn L. Bainbridge**. Nocturnal Involuntary Muscle Movement Associated with the use of Gabapentin. Family Medicine. Under Review.

Edward H. Maa, **Jacquelyn L. Bainbridge**, Chantal O'Brien, Robert T. Neuman, Mark C. Spitz. Unpredictability of Gastric Absorption of Oral Levetiracetam in Critically Ill Patients. Under Review.

Edward H. Maa, **Jacquelyn L. Bainbridge**, Kevin J. Staley, Mark C. Spitz. Oral Bumetanide Add-on Therapy in Refractory Adult Temporal Lobe Epilepsy. Under Review.

“When to Educate Health Care Professionals”. National Institute of Neurological Disorders and Stroke Workshop on Sudden Unexpected or Unexplained Death in Epilepsy (SUDEP). **Jacquelyn L. Bainbridge** and Andres Kanner (moderators). There are approximately eight groups that have submitted writing pieces. I was part of the original task force of this International expert's committee. The writing of this document was by group leaders (moderators) then put together in sections as a committee. November 12-14, 2008 was the meeting. The publication will be submitted to a neurology journal in 2010. Under Review.

Refereed Journals (Peer Reviewed)/ Published

Picchietti DL, Hensley JG, **Bainbridge JL**, Lee KA, Manconi M, McGregor JA, Silver RM, Trenkwalder C, Walters AS. Consensus Clinical Practice Guidelines for the Diagnosis and Treatment of Restless Legs Syndrome/Willis-Ekbom Disease During Pregnancy and Lactation. *Sleep Med Rev.* 2014 Oct 28. doi: 10.1016/j.smrv.2014.10.009. [Epub ahead of print]

Jacquelyn L. Bainbridge, Ellen Whipple Guthrie. Multiple Sclerosis: Managing the Whole Patient. This is part 1 of a series of articles and web-based teaching. This activity was originally presented at APhA in 2012, and then published on line 2013. POWER-PAK C.E. WWW.nabp.net/programs/cpe-monitor/cpe-monitor-service.

Jacquelyn L. Bainbridge, Sheldon J. Rich, Ellen Whipple Guthrie. Evolution of Treatment Strategies in Multiple Sclerosis. Current Issues for Managed Care and Specialty Pharmacists. POWER-PAK C.E. This is case 1 of a series of articles and web-based teaching. This activity was originally presented on line then published. 2013. WWW.nabp.net/programs/cpe-monitor/cpe-monitor-service.

Jacquelyn L. Bainbridge, Ellen Whipple Guthrie. Evolution of Treatment Strategies in Multiple Sclerosis. POWER-PAK C.E. This is case 2 of a series of articles and web-based teaching. This activity was originally presented on line then published. 2013. WWW.nabp.net/programs/cpe-monitor/cpe-monitor-service.

Lisa Hong, Jacquelyn Bainbridge. Anticonvulsant effects of SSRIs. *Mental Health Clinicians*. 2012;2(5):19 Available at: <http://cpnp.org/resource/mhc/2012/11/anticonvulsant-effects-ssris/>

Anne E. Eudy, Jacquelyn Bainbridge. Clinical Pearls for Chronic Use of Antiepileptic Drugs. *Mental Health Clinicians*. 2012;2(5):20. Available at: <http://cpnp.org/resource/mhc/2012/11/clinical-pearls-chronic-use-antiepileptic-drugs>.

Caleb Oh, Jacquelyn Bainbridge. Lowering the Seizure Threshold Associated with Antidepressants, Stimulants, Antipsychotics, and Others. *Mental Health Clinicians*. 2012;2(5):21. Available at: <http://cpnp.org/resource/mhc/2012/11/lowering-seizure-threshold-associated-antidepressants-stimulants-antipsychotics>.

Jacquelyn Bainbridge, Ellen Whipple Guthrie. Multiple Sclerosis: Managing the Whole Patient. *Pharmacy Today*. American Pharmacists Association. December 2012:66-76.

Anne M. Libby, Vahram Ghushchyan, Robert Brett McQueen, Julia F. Slejko, **Jacquelyn Bainbridge**, Jonathan D. Campbell. Economic Differences in Direct and Indirect Costs between People With Epilepsy and Without Epilepsy: Samples of U.S. National Populations". *Med Care* 2012; 50: 928-933. *Outcomes research*. 2012.

The NINDS NET-PD Investigators. There are several authors on this project with all authors contributing to data collection, care of patients, and finally writing of the publication. Design Innovations and Baseline Findings in a Long-Term Parkinson's Trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. *Movement Disorders* 2012;27(12):1513-1521. **(Research Article)**

Robert Lee Page II, Patrice Spurck, **Jacquelyn Bainbridge**, Julie Michalek, Robert Quaife. Seizures associated with regadenoson: A case series. *Nuclear Cardiology Bulletin*. Doi: 10.1007/s12350-011-9461-1. 15 October 2011. *Inprint J Nucl Cardiol* 2012 Apr;19(2):389-391.

Kavita V Nair, John Corboy, Kristijan Kahler, Richard Read Allen, Vahram Ghushchyan, Robert Brett McQueen, Jacci Bainbridge, Homa Dastani, Nikita Mody-Patel. Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis. *Expert Rev. Neurother.* 11(6),787-798 (2011). www.Expert-reviews.com

Jacquelyn Bainbridge. Current and Emerging Therapies in the Management of Multiple Sclerosis. Pharmacy Today. American Pharmacists Association. May 2011:63-75.

Zac Haughn, **Jacquelyn Bainbridge** (Senior and corresponding author). “Recognize and Prevent Polypharmacy in MS Patients. Practical Neurology September/October 2010: 22-27.

Michael Egeberg, J. Scott Bainbridge, **Jacquelyn L. Bainbridge** (Senior and corresponding author). “Managing Chronic Noncancer Pain With Opioids: A Case Approach for the Pharmacist”. Available at <http://www.thecsolution.com>. July 15, 2010. (1.5 hours ACPE)

Jacquelyn Bainbridge, Stephen Setter, Bradley Williams. “The Pharmacist’s Role in the Early Management of Parkinson’s Disease”. Supplement to Pharmacy Today. APhA Special Report. June 2010. (1.0 Hour of ACPE).

Jacquelyn L. Bainbridge, Mark Ruscin. The Challenges of Treatment Adherence in Elderly Patients with Parkinson’s Disease. Drugs and Aging 2009; 26 (2): 145-155.

Elson L. So, **Jacquelyn Bainbridge**, Jeffrey R. Buchhalter, Jeanne Donalty, Elizabeth J. Donner, Alexandra Finucane, Nina M. Graves, Lawrence J. Hirsch, Georgia D. Montouris, Nancy R. Temkin, Samuel Wiebe, Tess L. Sierzant. Report of the American Epilepsy Society and the Epilepsy Foundation Joint Task Force on Sudden Unexplained Death in Epilepsy. Epilepsia 2008;(01) 906:1528-1167. The writing of this document was by group leaders then put together in sections as a committee. All group leaders (this includes me) were involved in the original thought process of what should be included and discussed. All group leaders contributed extensively to the writing of this article.

The NINDS NET-PD Investigators. There are several authors on this project with all authors contributing to data collection, care of patients, and finally writing of the publication. A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results. Clin Neuropharmacol 2008;(3) 31:141-150.

Patrick D. Mauldin, Paulo Guimaraes, Roger L. Albin, E. Ray Dorsey, **Jacquelyn L. Bainbridge**, Andrew Siderowf. Optimal Frequency for Measuring Health Care Resource Utilization in Parkinson’s Disease Using Participant Recall: The FS-TOO Resource Utilization Substudy. Clinical Therapeutics 30:1553-1557. Aug 2008.

Core Elements of Epilepsy Diagnosis and Management: Expert Consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) Faculty. Tracy Glauser, Raman Sankar (Co-chairs), (Faculty) **Jacquelyn L. Bainbridge**, Martina Bebin, Selim R. Benbadis, et al. There are 26 Lead Faculty in all. *Current Medical Research and Opinion* 2008; 24(12):3463-3477. All authors contribute equally to the concept, collection of data, discussing the results and writing the manuscript.

Eugene Ramsay, Mark Spitz, **Jacquelyn L. Bainbridge**. Topiramate in Older Patients with Partial-onset Seizures: A pilot double-blind, dose-comparison study. *Epilepsia*. 49(7):1180-1185. 2008.

Patrick D. Mauldin, Paulo Guimaraes, Roger L. Albin, E. Ray Dorsey, **Jacquelyn L. Bainbridge**, Andrew Siderowf for the NINDS NET-PD Investigators. Optimal Frequency for Measuring Health Care Resource Utilization in Parkinson's Disease Using Participant Recall: The FS-TOO Resource Utilization Sub-Study. *Clin Ther*. 2008;30:1553-1557.

Jacquelyn L. Bainbridge, Robert Lee Page II, J. Mark Ruscin. Elucidating the Mechanism of Action and Potential Interactions of MAO-B Inhibitors. Positively Affecting Patient Outcome in Parkinson's Disease Management. Supplement To *Neurology Clinics*. *Neurol Clin* 26 (2008) S85-S96.

Robert Lee Page II, J. Mark Ruscin, **Jacquelyn L. Bainbridge**, Andreas A. Brieke. Restless Legs Syndrome Induced by Escitalopram: Case Report and Review of the Literature. *Pharmacotherapy* 2008;28(2):271-280.

Turner CJ, Ellis S, Giles J, Maffeo C, Hansen L, Saseen JJ, Ulrich H, Valdez C, Altieri R, **Bainbridge J**, Page R, Sintek C, Vondracek S, Zadvorny E, Fish D. A strategy to develop advanced pharmacy practice experiences. *Am J Pharm Educ*. June 15, 2007.

Robert L. Page II and **Jacquelyn L. Bainbridge**. Intractable Epistaxis Associated with Topiramate Administration. *Ann Pharmacother* 2006;40:1462-1465.

The NINDS NET-PD Investigators. There are several authors on this project with all authors contributing to data collection, care of patients, and finally writing of the publication. A Randomized Clinical Trial of Coenzyme Q₁₀ and GPI-1486 In Early Parkinson's Disease. *Neurology* 2007;68:20-28.

B.C. Tilley, Y.Y. Palesch, K. Kieburtz, B. Ravina, P. Huang, J.J. Elm, K. Shannon, G.F. Wooten, C.M. Tanner, G.C. Goetz on behalf of the NET-PD Investigators (including) **Jacquelyn L. Bainbridge**. Optimizing the Ongoing Search for New Treatments for Parkinson's Disease: Using Futility Designs. *Neurology* 2006;66:628-633.

The NINDS NET-PD Investigators. There are several authors on this project with all authors contributing to data collection, care of patients, and finally writing of the publication. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology* 2006;66:664-671.

Jacquelyn L. Bainbridge, Barry Gidal. What Role Will Natalizumab® Play in MS Management? Here's a Preview. *Practical Neurology*. February 2005; 4:2:74.

Jacquelyn L. Bainbridge, Barry E. Gidal, Melody Ryan. The ketogenic diet. *Pharmacotherapy* 1999;19(6):782-786.

Gottwald MD, **Bainbridge JL**, Dowling GA, Aminoff MJ, Alldredge BK. New pharmacotherapy for Parkinson's disease. *The Annals of Pharmacotherapy* 1997;31:1205-1216.

Chase PA, **Bainbridge JL**. Care plan for documenting pharmacist activities. *Am J Hosp Pharm*. 1993;50:1885-1888.

Fish DN, **Bainbridge JL**, Peloquin CA. Variable disposition of ciprofloxacin in patients undergoing continuous arteriovenous hemodiafiltration. *Pharmacotherapy* 1995;15(2):236-245.

B. Nonrefereed Journals

Bainbridge J. Drug therapy for Parkinson's Disease and adherence to therapy. *Towards Improved Adherence In Parkinson's Disease Therapy: The Key Role of Pharmacists*. Available at <http://www.powerpak.com/course/preamble/107857>. Published October 3, 2011.

Jacquelyn L. Bainbridge. APhA Special Report. The Pharmacist's Role in the Early Management of Parkinson's Disease. 1 hour of CEU's. www.pharmacist.com June 2010.

Jacquelyn L. Bainbridge. All Over The Map. *Academia Extends It's Global Reach*. *AACP Academic Pharmacy Now*. Jul/Aug/Sep 2008;1(4).

Jacquelyn L. Bainbridge. Alternative Medicine and Epilepsy. Newsletter for the Epilepsy Foundation of Colorado. September, 2002.

Jacquelyn L. Bainbridge. Pharmacy Informational Databases: Raising the Standard of Care. An Interview with a provider and User. USPharmacist. October, 2000.

C. Review Articles

Michael D. Egeberg, Caleb Y. Oh, **Jacquelyn L. Bainbridge**. Clinical Overview of Dalfampridine: The Agent with Novel Mechanism of Action to Help with Gait Disturbances. Clinical Therapeutics. 2012;34:2185-2194.

Robert Lee Page II, Patrice Spurck, **Jacquelyn L. Bainbridge**, Julie Michalek, Robert A. Quaife. Seizures associated with regadenoson: A case series. Nuclear Cardiology Bullet. Published online: 15 October 2011. In Print 2012.

Joseph P. Vande Griend, Sunny A. Linnebur, **Bainbridge, Jacquelyn L.** Probable Levetiracetam – Associated Depression in the Elderly: Two Case Reports. Am J Geriatr Pharmacother. 2009;7:281-284.

Bainbridge, Jacquelyn L., Anderson, Kathleen. An Update of Antiepileptic Drugs and Guidelines for Treatment. Clinical Pharmacy Newswatch. 2001.

D. Book Chapters

Jacquelyn L. Bainbridge. Chapter 5. Rounding, Documentation, and Patient Education. In: Neimire R, Kier K. eds. Pharmacy Student: A Survival Guide. Third Edition. New York: McGraw Hill, 2014.

Jacquelyn Bainbridge. Epilepsy and Headache/Migraine. Updates in Therapeutics: Ambulatory Care Pharmacy Preparatory Review Course. American College of Clinical Pharmacy. 2014 Edition Volume .

Jacquelyn L. Bainbridge, Pei Shieen Wong/Caleb Oh. Chapter 5. Rounding, Documentation, and Patient Education. In: Neimire R, Kier K. eds. Pharmacy Student: A Survival Guide. Third Edition. New York: McGraw Hill, 2014.

Jacquelyn L. Bainbridge, Mark C. Spitz, Pei Shieen Wong. Chapter 53.

Phenobarbital and Primidone. In: Elaine Wyllie, Barry Gidal, Howard Goodkin, Joseph Sirven, Tobias Loddenkemper, eds. Wyllie's Treatment of Epilepsy, 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2014.

Jacquelyn L. Bainbridge, Caleb Y. Oh. Chapter 12. Antiepileptic Drug Adverse Effects to Watch Out For. In: John W. Miller and Howard Goodkin eds. Epilepsy (Neurology in Practice Series). Oxford OX4 2DQ: Wiley-Blackwell, 2013.

Jacquelyn Bainbridge. Epilepsy and Headache/Migraine. Updates in Therapeutics: Ambulatory Care Pharmacy Preparatory Review Course. American College of Clinical Pharmacy. 2013 Edition Volume 2 .

Jacquelyn L. Bainbridge, Jeffrey K. Clark, and Edward H. Maa. Chapter 40 Epilepsy. In: Rebecca L. Attridge, Monica L. Miller, Rebecca Moote, Laurajo Ryan, eds. Internal Medicine A Guide to Clinical Therapeutics. China: McGraw-Hill Companies, 2013.

Michael D. Egeberg, **Jacquelyn L. Bainbridge**, and Jeffrey K. Clark. Chapter 41 Multiple Sclerosis. . In: Rebecca L. Attridge, Monica L. Miller, Rebecca Moote, Laurajo Ryan, eds. Internal Medicine A Guide to Clinical Therapeutics. China: McGraw-Hill Companies, 2013.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter. Multiple Sclerosis. In: Schwinghammer TL, Koehler JA. Eds. Pharmacotherapy Casebook: a patient-focused approach. 8th ed. New York: McGraw Hill, 2013.

Jacquelyn L. Bainbridge, Augusto Miravalle and John R. Corboy. Chapter 39. Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York: McGraw Hill, 2013.

Jacquelyn Bainbridge. Epilepsy and Headache/Migraine. Updates in Therapeutics: Ambulatory Care Pharmacy Preparatory Review Course. American College of Clinical Pharmacy. 2012 Edition Volume 1.

William R. Garnett, **Jacquelyn L. Bainbridge**, Michael Egeberg and Sarah Johnson. Chapter . Newer Antiepileptic Drugs. In: Murphy JE, Clinical Pharmacokinetics 5th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, 2012.

William R. Garnett, **Jacquelyn L. Bainbridge**, Michael Egeberg, and Sarah L. Johnson. Chapter . Ethosuximide. In: Murphy JE, Clinical Pharmacokinetics 5th ed. Bethesda, Maryland: American Society of

Health-System Pharmacists, 2012.

Edward H. Maa, Michael P. Earnest, Mark C. Spitz, **Jacquelyn Bainbridge**. Chapter 14. Severity of Seizures as a Forensic Risk and Case Reports. In: Claire M. Lathers, Paul L. Schraeder, Michael W. Bungo, Jan E. Leestma, eds. Sudden Death in Epilepsy: Forensic and Clinical Issues. Boca Raton, Florida: CRC Press, 2011.

Jacquelyn L. Bainbridge and John R. Corboy. Chapter 64. Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw Hill, 2011.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 63. Multiple Sclerosis. In: Schwinghammer TL, Koehler JA. Eds. Pharmacotherapy Casebook: a patient-focused approach. 8th ed. New York: McGraw Hill, 2011.

Jacquelyn Bainbridge. Epilepsy and Headache/Migraine. Updates in Therapeutics: Ambulatory Care Pharmacy Preparatory Review Course. American College of Clinical Pharmacy. 2011 Edition Volume 1.

Jacquelyn L. Bainbridge. Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. Laura Borgelt, Karim Anton Calis, Mary Beth O'Connell, Judith A. Smith Epilepsy and Multiple Sclerosis. Section editor of the Neurologic Disorders chapters. Chapter 41. American Society of Health-System Pharmacists 2010.

Sarah Johnson, **Jacquelyn L. Bainbridge**, Ruth Taggart, Janina Janes. Chapter 5. Rounding, Documentation, and Patient Education. In: Neimire R, Kier K. eds. Pharmacy Student: A Survival Guide. Second Edition. New York: McGraw Hill, 2009.

Jacquelyn L. Bainbridge and John R. Corboy. Chapter 57. Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York: McGraw Hill, 2008.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 58. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Casebook: a patient-focused approach. 7th ed. New York: McGraw Hill, 2008.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 58. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Instructor

Casebook: a patient-focused approach. 7th ed. New York: McGraw Hill, 2008.

William R. Garnett, **Jacquelyn L. Bainbridge**, and Sarah L. Johnson. Chapter 6. Newer Antiepileptic Drugs. In: Murphy JE, Clinical Pharmacokinetics 4th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, 2008.

William R. Garnett, **Jacquelyn L. Bainbridge**, and Sarah L. Johnson. Chapter 8. Newer Antiepileptic Drugs. In: Murphy JE, Clinical Pharmacokinetics 4th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, 2008.

William R. Garnett, **Jacquelyn L. Bainbridge**, and Sarah L. Johnson. Chapter 10. Newer Antiepileptic Drugs. In: Murphy JE, Clinical Pharmacokinetics 4th ed. Bethesda, Maryland: American Society of Health-System Pharmacists, 2008.

Bainbridge JL. Headache In: Brundage D, Winkler S, eds. Pharmacotherapy Self-Assessment Program, 5th ed. Chronic Illness. Kansas City, MO: American College of Clinical Pharmacy, 2005: 117-139.

Jacquelyn L. Bainbridge, John Corboy. Chapter 53. Treatment of Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy. 6th ed. New York: McGraw Hill, 2005.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 58. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Casebook: a patient-focused approach. 6th ed. New York: McGraw Hill, 2005.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 58. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Instructor Casebook: a patient-focused approach. 6th ed. New York: McGraw Hill, 2005.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 60. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Casebook: a patient-focused approach. 5th ed. New York: McGraw Hill, 2002.

Jacquelyn L. Bainbridge, John R. Corboy. Chapter 60. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Instructor Casebook: a patient-focused approach. 5th ed. New York: McGraw Hill, 2002.

Jacquelyn L. Bainbridge, John Corboy. Treatment of Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy. 5th ed. Stamford, CT: Appleton & Lange, 2002.

Jacquelyn L. Bainbridge, Janes JZP, Pollock DS. Novel mechanisms of drug delivery. In: Rho Jong M, Sankar R, Cavazos JE, eds. Epilepsy Scientific Foundations of Clinical Practice. New York, New York: Marcel Dekker, 2004:421-436.

Jacquelyn L. Bainbridge. Alternative Therapies and Drug Interactions in Patients with Epilepsy. Fight Against Childhood Epilepsy & Seizures Complementary and Alternative Therapies. 2002.

Barry E. Gidal, **Jacquelyn L. Bainbridge**. Chapter 60. Multiple Sclerosis. In: Schwinghammer TL. Eds. Pharmacotherapy Casebook: a patient-focused approach. 5th ed. New York: McGraw Hill, 2003.

Jacquelyn L. Bainbridge, Janina Janes, Ruth Taggart. Chapter 12. Meeting Preceptor's Expectations: Rounding, SOAP Notes, Patient Education. In: Neimire R, Kier K. eds. Pharmacy Clerkship Manual: A Survival Manual for Students. New York: McGraw Hill, 2002.

Jacquelyn L. Bainbridge, John Corboy, Barry Gidal. Treatment of Multiple Sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy. 5th ed. Stamford, CT: Appleton & Lange, 2002.

E. Abstracts/Presentations (published)

AES Lacosamide in the Elderly. 12/2014

S. Dunlap, K Lervik, J. Bainbridge, L. Strom. Objective Self-Measurement of the Subjective Side Effect of Dizziness on Sodium Channel Blocking AEDS. Epilepsia. AES meeting Washinton DC, 12/2013. Honors Project.

S. Merrill, PS. Wong, R. Page, J Bainbridge. Antiepileptic Drug Risks and Safety in Patients with Heart Failure and Heart Block. Epilepsia. AES meeting Washinton DC, 12/2013. Honors Project.

Jacquelyn L. Bainbridge, Mark Spitz, Selim Benbadis, Steven Chung, Barbara Phillips, Joseph Sirven, Edward Maa. A Multi-Center Retrospective Study of Lacosamide in the Elderly (≥ 60 years of age). Epilepsia. AES meeting Washington DC.

Holly L. Cooper, **Jacquelyn L. Bainbridge**, Michael Egeberg, Jeffrey K. Clark, Mark Spitz, Selim Benbadis, Melissa Freeman, Barbara Phillips,

Joseph Sirven, Edward Maa. A Multi-Center Retrospective Study of Lacosamide in the Elderly (≥ 60 years of age). Epilepsia. AES meeting Baltimore. 12/2011.
12/2013.

Holly L. Cooper, **Jacquelyn L. Bainbridge**, Michael Egeberg, Jeffrey K. Clark, Mark Spitz, Selim Benbadis, Melissa Freeman, Barbara Phillips, Joseph Sirven, Edward Maa. A Multi-Center Retrospective Study of Lacosamide in the Elderly (≥ 60 years of age). Epilepsia. AES meeting Baltimore. 12/2011.

Jacquelyn L. Bainbridge, Ellen Whipple-Guthrie, Augusto Miravalle, Sheldon J. Rich. The Clinical Challenges of Multiple Sclerosis: Managed Care and Specialty Pharmacist Perspectives. Written CE Booklet, Live Presentation, Four Webcast series presented live, and two interactive case series. 2012. (1.5 hours each). **Chair** and organizer of this Webcast and Publication.

A Multi-Center Retrospective Study of Lacosamide (Vimpat®) in the Elderly (> 60 years of age)

Mark Spitz, Jacquelyn Bainbridge. Lacosamide in the Adult Patient Population. Epilepsia. Presented in San Antonio, TX. December, 2010

Jacquelyn L. Bainbridge, Melody Ryan, Sheldon Rich. John Hopkins Advanced Studies in Medicine Multiple Sclerosis Journal Club. Accredited by University of Tennessee/Advanced Studies in Pharmacy Program. Module 2. “Evaluating the Clinical Course and Pathology of Multiple Sclerosis. Webinar. July 2010.

Jacquelyn L. Bainbridge, Melody Ryan, Sheldon Rich. John Hopkins Advanced Studies in Medicine Multiple Sclerosis Journal Club. Accredited by University of Tennessee/Advanced Studies in Pharmacy Program. Module 1. “Critical Papers in Multiple Sclerosis: From Evidence to Practice For Managed Care Pharmacists”. Webinar. June 2010.

Jacquelyn L. Bainbridge, Ellen Whipple-Guthrie, Augusto Miravalle, Sheldon J. Rich. “The Evolving Paradigms in Multiple Sclerosis: Focus on Early Identification and Treatment Initiation”. Written CE Booklet, Live Presentation and Four Webcast series presented live. August 10, August 17, August 31, and September 14, 2010. (1.5 hours each). **Chair** and organizer of this Webcast and Publication.

Kavita Nair, Jacquelyn L. Bainbridge. “Utilization of Diagnostic Tests and Procedures for Treated and Untreated Patients with Multiple Sclerosis (MS)”. Presented at the American Academy of Neurology. Toronto, ON, Canada. April 10-17, 2010.

E. Maa, J.Bainbridge, K.Ehrenreich-Piot, M. Spitz. Safety and Efficacy of Intravenous Levetiracetam in Subarachnoid Hemorrhage. Poster #:3.230. (abstract). *Epilepsia*. 2008;49(suppl. 7):.

Jacquelyn L. Bainbridge. Switching From Immediate-Release to Extended-Release Carbamazepine: Efficacy and Seizure Control. Poster #:2.341. (abstract). *Epilepsia*. 2005;46(suppl. 8):205.

Mark C. Spitz, **Jacquelyn L. Bainbridge,** Eugene R.Ramsey, Basim M. Utham, Flavia Pryor, Brenda Smith, Vanessa Winzenburg, Sharon Edwards. Observations on the delay in the diagnosis of seizures in the elderly: Update 3 (abstract). *Epilepsia*. 2003;43(suppl.7):166.

Mark C. Spitz, **Jacquelyn L. Bainbridge,** Eugene R.Ramsey, Basim M. Utham, Flavia Pryor, Brenda Smith, Vanessa Winzenburg, Sharon Edwards. Observations on the delay in the diagnosis of seizures in the elderly: Update 2 (abstract). *Epilepsia*. 2002;43(suppl.7):166.

Mark C. Spitz, **Jacquelyn L. Bainbridge,** Eugene R.Ramsey, Basim M. Utham, Flavia Pryor, Brenda Smith, Vanessa Winzenburg, Sharon Edwards. Observations on the delay in the diagnosis of seizures in the elderly: Update (abstract). *Epilepsia*. 2001;42(suppl.7):144.

Johnson J, Pryor FM, Ramsay RE, Rowan AJ, DeToledo J, DVA CSP 428 Study Group (**Bainbridge, JL**). Recruitment of elderly patients in clinical trials (abstract). *Epilepsia* 2001; 42:142.

Pryor FM, Ramsay RE, Rowan AJ, Resillez M, DVA CSP 428 Study Group (**Bainbridge, JL**). Utility of extended EEG recordings in the diagnosis of epilepsy in the elderly (abstract). *Epilepsia* 2001; 42:27.

Rowan AJ, Ramsay RE, Pryor FM, Collins JF, DVA CSP 428 Study Group (**Bainbridge, JL**). Seizures in the elderly population: Interim report of VA Cooperative Study 428 (abstract). *Epilepsia* 2001; 42:143.

Mark C. Spitz, **Jacquelyn L. Bainbridge,** Eugene R.Ramsey, Basim M. Utham, Flavia Pryor, Brenda Smith. Observations on the delay in the

diagnosis of seizures in the elderly (abstract). *Epilepsia*. 2000;41(suppl.41):109.

Johnson J, Pryor FM, Ramsay RE, Rowan AJ, DeToledo JC, DVA CSP 428 Study Group (**Bainbridge, JL**). Clinical trials: Recruitment challenges in the elderly (abstract). *Epilepsia* 41[(Suppl 7)], 109. 2000.

Pryor FM, Ramsay RE, Rowan AJ, Collins JF, DVA CSP 428 Study Group (**Bainbridge, JL**). Diagnostic, demographic and retention issues in managing seizures in older patients (abstract). *Neurology* 2000; 54:A84-A85.

Ramsay RE, Rowan AJ, Pryor FM, Collins JF, DVA CSP 428 Study Group (**Bainbridge, JL**). Seizures in the older patient: Demographics, diagnosis, and treatment (abstract). *Epilepsia* 2000; 41:172-173.

Scott D. Pollock, Mark C. Spitz, **Jacquelyn L. Bainbridge**, Sheri J. Friedman. Catamenial pattern in a population of women with refractory epilepsy (abstract). *Epilepsia*. 2000;40(suppl.2):200.

Sunita Dergalust, **Jacquelyn L. Bainbridge**. Efficacy of gabapentin in the treatment of peripheral neuropathy in individuals with HIV infection (abstract). *Epilepsia*. 2000;40(suppl.2):230.

J. Bainbridge, S. Pollock, J. Adams, P. Levisohn. Adverse effects of topiramate use in children (abstract). *Epilepsia*. 1999;40(suppl.2):181.

Jacquelyn L. Bainbridge, Franklin T. Lum, Mark C. Spitz. Management of antiepileptic drugs in solid organ transplant patients (abstract). *Epilepsia*. 1999;40(suppl. 7):228.

Pryor FM, Ramsay RE, Rowan AJ, Collins JF, DVA CSP 428 Study Group (**Bainbridge, JL**). Treatment of seizures in the elderly: Demographics, diagnosis & retention (abstract). *Epilepsia* 1999; 40:106.

Barry E. Gidal, Raj D. Sheth, **Jacquelyn L. Bainbridge**, Eugene Ramsey, Timothy E. Welty, Karen J. Weatherford, Frank Gilliam, Bruno V. Gallo, Brian K. Alldredge, Georgia D. Montouris, Daryn S. Belden, Annette Lenner. Alternative medicine (AM) use in epilepsy: results of a national, multicenter survey (abstract). *Epilepsia*. 1999;40(suppl.7):107-108.

Bainbridge JL, Shantz DL, LaClaire S. The tolerability of depakote® in the elderly (abstract). *Epilepsia*. 1998;39(suppl. 6):127.

Bainbridge JL, Fish DN, Shantz DL, Spitz MC. Quality of life in Epilepsy at The University of Colorado Health Sciences Center (abstract). *Epilepsia*. 1997;38(suppl.8):182.

Spitz MC, Clover T, Shantz DL, **Bainbridge JL**. Profuse sweating as an ictal phenomenon (abstract). *Epilepsia*. 1997;38(suppl. 8):54.

F. Book Reviews and Letters

Jacquelyn L. Bainbridge. Treatment-Resistant Mood Disorders: Diagnosis and Treatment. In: Jay D. Amsterdam, Mady Hornig and Andrew A. Nierenberg eds.. New York, NY: Cambridge University Press Inc., 2001. xvii+ 535pp. Book review. Published in *American Journal of Pharmaceutical Education*. 2002;66:343-344.

Jacquelyn L. Bainbridge. Experimental and Clinical Neurotoxicology. In: Peter S. Spencer, Herbert H. Schaumburg eds. New York, NY: Oxford University Press, 2000. XI+ 1310pp. Book review. Published in *American Journal of Pharmaceutical Education*. 2000;64:335-336.

Jacquelyn L. Bainbridge. Neuroinflammation – Mechanisms and Management. In: Paul L. Wood ed.. Totowa NJ: Humana Pres, Inc., 1998. x + 375 pp. Book review. Published in *American Journal of Pharmaceutical Education*. 1998;62:360.

Jacquelyn L. Bainbridge. Introduction and objectives for the treatment of epilepsy. *Med/Pharm Forum*. American College of Clinical Pharmacy 1997 Annual Meeting Proceedings, Continuing Education Credit, 3CEU's. 1998.

Bunch C, **Bainbridge JL**. Letter to the editor. *American Journal of Health-System Pharmacy*. 02/1998.

G. Other Publications

Jacquelyn Bainbridge. Sharon Park. Can you feel it? Neurology treatments moving forward. Interview. February 2014. *Pharmacy Today*

Jacquelyn Bainbridge. *Neurology Naplex PharmPrep*. 2011.

Jacquelyn Bainbridge. Epilepsy Foundation of Colorado and Epilepsy Foundation of America. Medicines for Epilepsy brochure.

Jacquelyn L. Bainbridge. What Is a Seizure LEAD brochure and contributed as a faculty member - Managing Your Epilepsy Treatment, Women and Pregnancy. October, 2009.

Jacquelyn Bainbridge. 2009 Update on the Science of Multiple Sclerosis:Managed Care Pharmacist Perspectives.Advanced Studies in Pharmacy. 2009;6(3):50-82.

Jacquelyn Bainbridge. Epilepsy 51 -y/o Perimenopausal Woman with Tonic-Clonic Seizures December 2009. LEAD initiative.

Jacquelyn Bainbridge. 2009 Fibromyalgia Syndrome: Care and Controversies. Advanced Studies in Pharmacy. 2009;6(5):126-163.

Jacquelyn L. Bainbridge. All Over the Map: Pharmacy Academia Extends Its Global Reach. Academic Pharmacy NOW. Volume 1, Issue 4. Jul – Sept 2008.

Jacquelyn L. Bainbridge. Parkinson's disease Journal Supplement. April, 2008. TEVA Neurosciences 2008.

Epilepsy Foundation of America, Advocacy Committee, **Jacquelyn L. Bainbridge.** Underwritten by an unrestricted educational grant from UCB Pharma, Inc. H.O.P.E. Helping Other People with Epilepsy. Brochure 2008.

Debbie Stern, **Jacquelyn L. Bainbridge,** Patricia K. Coyle. Treatment Optimization Strategies for Multiple Sclerosis. Clinical Monograph. February 2007.

Jacquelyn L. Bainbridge. Case Study: Pregnancy in Patient with Partial Onset Seizures. NeuroNews. January 2007.

Jacquelyn L. Bainbridge. Management of Pain: Balancing Efficacy with Safety and Tolerability (Pharmacists). Pharmacy Rounds. SynerMed Communications. April 30, 2007.

Jacquelyn L. Bainbridge. Epilepsy and Pregnancy. NeuroNews. (CE included for this publication) Volume1, Issue 3. Spring 2007.

Jacquelyn L. Bainbridge. Treatment Optimization Strategies For Multiple Sclerosis. Consensus Medical Communications. (CE included for this publication) February 2007.

Jacquelyn L. Bainbridge. Pharmacy Rounds Newsletter – Management

of Pain: Balancing Efficacy with Safety and Tolerability (CME). Volume 2, No. 1. April 2007.

Bainbridge, Jacquelyn L. Treatment Optimization Strategies for Multiple Sclerosis: Working to Improve Outcomes While Managing Costs. Consensus Medical Communications. March, 2007.

Bainbridge, Jacquelyn L. Neuropharmacology of Antiepileptic Drugs. (CE included with this publication). This was part of an annual series. American Epilepsy Society. 2007.

Bainbridge, Jacquelyn L. A comparison of safety and tolerability in epilepsy patients transitioned from immediate-release carbamazepine (Tegretol®) to extended-release carbamazepine (Carbatrol®). Poster. AES Scientific Exhibit, December 3, 2006.

Bainbridge, Jacquelyn L. A comparison of safety and tolerability in epilepsy patients transitioned from generic immediate-release carbamazepine to Carbatrol® extended-release carbamazepine. Poster. AES Scientific Exhibit, December 3, 2006.

Bainbridge, Jacquelyn L. Neuropharmacology of Antiepileptic Drugs. (CE included for this publication). This was part of an annual series. American Epilepsy Society. 2006.

Bainbridge, Jacquelyn L. Transitioning from Immediate-Release to Extended-Release Carbamazepine: Efficacy and Seizure Control. Poster. AES Scientific Exhibit, December 5, 2005.

Bainbridge, Jacquelyn L. Late-Breaking News. Cranberry juice can cause bleeding. Bottom Line Health. Volume 19, Number 8. August 2005.

Jacquelyn L. Bainbridge. Multiple Sclerosis Clinicians Guidebook. Managed Health Care Executives. November, 2005;(suppl):1-76.

Jose R. Maldonado, Gerald A. Maccioli, Richard R. Riker, Joseph F. Dasta, Eva Szabo, **Jacquelyn L. Bainbridge.** Delirium in The ICU: Prevention and Treatment. PRESENTATIONS IN FOCUS. Rogers Medical Intelligence Solutions. 2005:1-22.

Bainbridge, Jacquelyn L. Natalizumab®. Practical Neurology. February 2005.

Bainbridge, Jacquelyn L. Neuropharmacology of Antiepileptic Drugs. AES. 2005.

Bainbridge, Jacquelyn L. Interview about Diet and Disabilities. September 2004.

Bainbridge, JL. Novel AEDs in Clinical Development. Interview. February 2004.

Jacquelyn L. Bainbridge. The Medical Management of Epilepsy. Pharmacy Tech Topics. Volume 9, NO. 4. October 2004.

Jacquelyn L. Bainbridge. MS immunomodulators. AJHP. 03/2004.

Bainbridge, JL. Novel Careers in Pharmacy. The Denver Post. November 2003.

Erickson AK. New MS therapy creates choices, confusion. *Pharmacy Today*. April 2002; pulse on therapy: clinical & medication trends:5.

Bainbridge, JL interviewed for article.

Bernstein LR. Pharmacy Informational Databases: Raising the Standard of Care. An interview with a provider and user. Vita Media Corporation, San Francisco, California. January 2000. **Bainbridge, JL** interviewed for article.

Bainbridge JL, Bunch CL. Treatment of Black Widow Spider Bites with Dantrolene Sodium. Micromedex® 1995.